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1.  INTRODUCTION 
Biotechnology  is  a  highly  technical  and  fast-growing  field  which  is  currently  governed 
according to the precautionary principle in the Community. Although safety represents a key 
element  in  existing  Community  legislation,  it is  at  the  ~arne time  essential  to  ensure that 
regulation  does  not unnecessarily hinder the  potential  for  technological  innovation.  This 
growth sector has not yet reached its full potential and its cruising speed.  In addition, this new 
technology will maintain the competitiveness of Europe on the world market and will make a 
major contribution to economy growth by enhancing the competitive position of industry and 
agriculture. 
The safety of activities involving modern biotechnology is currently ensured iri the European 
Union through four horizontal Directives (Directive 90/219/EEC,  90/220/EEC,  90/679/EEC 
and  94/55/EC)  and  sectoral  measures.  These  include  the  Novel  Food  Regulation,  which 
-entered into force in May 1997 and provides specific authorisation and notification procedures 
as well as labelling provisions for novel foods and food ingredients.  Other measures are under 
preparation, such as the Draft Novel Feed  Regulation, or in discussion in the Council and the 
European Parliament, such as the proposed "seeds" Directive. 
While Directive 90/219/EEC  covers  the  contained use - the use  in research  and  industrial 
facilities  - of genetically modified micro-organisms (GMMs),  Directive 90/220/EEC covers 
the deliberate release into the environment of genetically modified organisms (GMOs).  The 
latter covers  both deliberate releases  for  experimental purposes,  and  deliberate releases  for 
placing on the market of products. 
Directive  90/220/EEC came into  force  on 23  October  1991.  Since then more than  1,000 
experimental releases (Part B) have been notified to Member State Authorities and more than 
20  product notifications have .been submitted.  International experience elsewhere has  shown 
that these figures will increase rapidly in the next few years. 
Smce  1996,  the  summary  notification  information  formats  for  Part B  releases  have  been 
circulated between Member States and  the Commission under the responsibility of the JRC 
(ISIS).  At this stage all  experimental releases have been collected in a database available in 
lspra which can be CQnsulted by request of  the Competent Authorities of  Member States. 
·rn its Communication on Biotechnology and the White Paper on Growth, Competitiveness and 
Employment  (June  1994),  the  Commission  recognises  the- importance  of  modem 
biotechnology,  and  confirms  that  "in  the  future  the  whole  network  of  interrelated 
biotechnological regulations needs to  ensure that oversight is  always appropriate to the risks 
involved,  the  building  of public ·confidence  and  to  the  competitive  development  of the 
industries involved while guaranteeing the protection ofhuman health and the environment.~, 
As  far  as  Directive 90/220/EEC  was  concerned,  the  Communication  concluded  that  this 
"Directive was flexible  enough to  satisfy the  needs  of the time for  adaptation to  technical 
Biotechnology and the White Paper on Growtlt, Competitiveness and Employment, preparing the next stage. 
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progress and simplification of  the procedures," but it conclude~ that "there were aspects of  this 
Directive that might be improved in  the future"
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.  · 
It is  in this  context that the Commission adopted on  10  December  1996
3  a Report on the 
review of  Directive 90/220/EEC with the aim of assessing the need for changes with regard to 
the.objectives outlined in the Communication. 
The Report,  in which the  different parts  of Directive  90/220/EEC  are  carefully  analysed, 
concludes  that the  Directive  has  helped  Member  States  to  introduce the  appropriate  and 
necessary infrastructure for assessing potential human health and environmental effects from 
the  deliberate  release  of GMOs.  Its  implementation,  however;  has  revealed  a ·number  of 
. problem areas.  Recognising the need for a horizontal regulatory framework to  epsure high 
levels of safety for the environment and human· health and of transparency, the Commission 
indicated in the conclusions of the Report its intention to adopt a Proposal for an amendment 
of  Directive 90/220/EEC in the course of 1997.  ·. 
Directive  90/220/EEC  foresees  the  introduction  of product  based  Community  legislation 
which provides for a specific environmental risk assessment similar to that in the Directive. 
The Report considers the possibility of including in product legislation such a risk assessment 
which ·would  allow  the  relevant  Part B  releases  to  be  covered  by that legislation.  The 
Commission considers  that this  possibility should be included  in the Proposal since  it will 
promote the  link between releases  for  purposes  of research  and  development and  product 
releases. 
The current system for risk assessment which forms part of  the notification for placing on the 
market  under  Part  C  of  Directive  90/220/EEC,  is  decentralised  and  falls· under  the 
responsibility of the  Competent Authorities of the Member  States.  The  imp!ementation of 
such a system has  led to conflict, since the assessment of the notification by the forwarding 
Member State Competent Authority is usually not accepted by the other J\.1ember States. 
Based on the discussions  of the Risk Assessment Group  established in the framework of the 
Committee of Competent Authorities for Directive 90/220/EEC,  a common approach to  risk 
assessment objectives and methodology has been further developed by the Commission. 
rv1oreover,  the  cr~s~ of Bt-maize (Novartis) underlined the necessity of an indep-endent system 
for  conflict  resolution  which  would  allow  problems  to  be  discussed  and  resolved  on  a 
scientific basis as  in the case of Community legislation dealing with marketing authorisation 
fDr  foods, _pharmaceuticals  and feed.  The Proposal, therefore,  includes  an obligation for the 
Commission to  consult a Scientific Committee on any  matter in the clearance of applications 
for  placing  on  the  market  which  is  likely  to  have  an  effect  on  human  health  and  the 
environment. 
In proposing this  modification of Directive 90/220/EEC, the  Commission  has  reviewed the 
existing  provisions  in  the  light  of the  experience  of USA,  Canada  and  Japan  in  their 
assessment and  decision-making process for the release of GMOs  as well as  the international 
trade commitments linked to the placing on the market of genetically modified products.  The 
Bioteclmology and the White Paper on Growth, Competitiveness and Employment, preparing the nex1 stage. 
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3 p.r:ovisions in this Proposal also take  into account the specific sensitivity ·and awareness of  t9-e 
public in Europe concerning genetic~y  modified organisms. 
In the last 12 months, the placing~ on the market of genetically modified organisms has led to 
growing concern on the part of  the general public regarding the limited experience with certain 
use~.of  this new technology and criticisms have arisen regarding the lack of transparency in 
the decision-making process, including the difficulty of access  to the notification dossiers. 
The public has expressed the need for users of  genetically modified products to be fully aware 
of  the method by which these products have been produced so t;hat they can make an informed 
choice.  In order to meet these ·concerns, the Commission adopted on 18 June 1997 a technical 
adaptation of Annex III of Directive 90/220/EEC to  allow mandatory labelling of aU GMOs 
approved for placing on the market under the Directive.  The proposed  amendments  will 
maintain obligatory labelling for all GMOs  approved  for  placing on the ma*et under the 
Directive.:. 
The.  c~irent Directive 90/220/EEC does not provide for the possibility of a single procedure 
for  multi-state  experimental  releases.  As  the  field  develops  it will  increasingly  become 
necessary to test GMOs in more than one Member State.  The introduction of provisions for 
multi-state experimental releases will benefit notifiers and should promote  mutual recognition 
of the  risk  assessment  between  Member  States.  The  provisions  establishing  simplified 
procedures  under the  current Directive  are  not  repeated  in the  present  Proposal  but  the 
provisions adopted pursuant to Article 6 (5) of the current Directive ie Commission Decision 
94/730/EC  establishing  simplified  procedures  concerning  the  deliberate  release  into  the 
environment of genetically modified plants will remain applicable under the, present Proposal 
when adopted. 
As the field of Biotechnology develops, it may be possible to establish clearly defined criteria 
and  information  requirements  which  will  allow  to  apply  for  a  simplified  administrative 
procedure for  the  placing on the market of products  containing  or consisting of GMOs. 
However, the experience gained in the release of products is  at present not sufficient to  fix 
these  criteria.  The  Commission  will  prepare  a  proposal  for  criteria  and  information 
requirements for  the simplified procedure .as  soon as  possible  and when sufficient scientific 
knowledge and  experience is  available.  These criteria and  information requirements will be 
based on scientific evidence available and generally recognised and on the experience gained 
wi~h comparable releases.  The Proposal introduces  a simplified  procedure for  cases  where 
suth criteria and information requirements have been established according to  the Article 21 
p.rocedure.  The safety aspects will be ensured by the involvement of the relevant Scientific 
Committees in that procedure.  The simplified procedure introduced into the Proposal does not 
remove the right of Member States to raise objections and the obligation for the Commission 
to consult a Scientific Committee on any  matter in the clearance of applications for placing on 
the market which is likely to have an effect on human health and the environment. 
When adopting  its  Resolution on  16  July  1997  on  the  Report on the  Review of Directive 
90/220/EEC submitted by the· Commission, the European Parliament emphasised  the need to 
include the· possibility to deal with ethical concerns in the framework of the revision of the 
Directive.  The Proposal confirms the possibility of the Commission to consult any committee 
it has created with a view to advising it on the ethical implications of biotechnology  on any 
general matters which may raise.ethical concerns. 
4 A number of developments have taken place in the Community since the adoption of this 
Report by the Commission.  These developments have a direct impact on the contents of  this ' 
Proposal. 
Thus, 
- 1n its Communication on Consumer Health and Food Safety, adopted on 30 Aprill997, the 
Commission outlined its new approach· to  consumer health and food safety,  in particular 
with respect to scientific advice as well as to control and inspection.  In the Communication 
the  Commission  indicated  that "in order  to  implement  Commission  policy  concerning 
scientific  advice  on matters  relating  to  consumer  health,  it will  propose  or adopt  the 
necessary  acts  to  introduce,  where necessary,  compulsory  consultation  of a  Scientific 
Committee".
4  In this  context, for example,  Scientific Committees  can be consulted to 
determine if the presence of specific antibiotic resistance genes in a product could pose a 
risk to  human health and the environment.  The recently-adopted Commission Decisions 
creating the Scientific Committees enable, in certain cases, the Scientific Committees to be 
requested to deliver their opinion within a limited time period.  / 
- On 23  July 1997 the Commission adopted a broad orientation for an extended Community 
labelling system for GMO products in which it states that such a system should be broad, ' 
transparent, and scientifically-based in order to help in the tracing of these products. along 
the food chain.  This system results in 3 categories
5
:  · 
•  voluntary labelling ("this does not contain ... ") for certified non-GMO products, 
•  mandatory labelling ("this contains .... ") for products known to be of GMO origin, 
•  and mandatory labelling ("this may contain ... ") in cases where material of GMO  origin 
cannot be excluded but where no evidence of such material is available. 
- Finally, on 10 September 1997, when deciding to  adopt draft measures aimed at requesting 
the Member  States  which invoked  Article  16  of Directive  90/220/EEC to  ban or/and  to 
restrict the use and/or the placing on the market of Bt maize,  for which consent had been 
given on 5 February  1997 by the French authorities to  repeal their bans, the Commission 
concluded that any  weaknesses  in the legislation on  products  should be addressed  in  the 
framework of the revision of Directive 90/220/EEC.  In  this  context,  monitoring and  time 
limits were discussed. 
In a Ilia Committee procedure it is possible that there is no qualified majority in the Council in 
favour of a Commission Proposal nor unanimity against it.  In default of a decision on the part· 
of Council the fmal responsibility lies with the Commission.  This was the case of the Bt maize 
in  the  summer  of  1996.  By  opting  for  a  liTh  procedure,  the  Council  may  reject  the 
Commission proposal by simple majority.  This increases the role of the Member States in the 
decision-making process. 
The legal text will provide for products already granted  cons~nts for placing on the market to 
be reassessed within 7 years of  the date of entry into force of the amended Directive. 
The.Commission has thus taken into consideration 
Communication from the Commission on Consumer Health and Food Safety (COM(97)183 final), p.  14 
5 - the experience. gained in the implementation of  Directive 90/220/EEC; 
- the latest scientific data on the assessment of  deliberate releases; · 
- the exchange of  views which has taken.place in the Council on the possible amendment of 
Directive 90/220/EEC;  .  · 
- the outcome of the discussions in the European Parliament and the Economic and Social 
Committee on the Report on the Review of  Directive 90/220/EEC, and . 
- the developments which have taken place in the field of biotechnology since the adoption 
of  the Report .on the Review of  Directive 90/220/EEC. 
The review process  of Directive 90/220/EEC has involved  extensive  consultation with the 
stakeholders,  the · Competent  Authorities  of  Member  States,  Industrial  and  Research 
Associations, Environmental, Consumer and Trade Union Organisations. 
2.  OBJECTIVES 
Directive 90/220/EEC regulates a high-technology field,  which is  developing rapidly.  The 
Directive covers both the stages of development and the placing on the market of products 
containing or consisting of GMOs.  The objectives of  the present Proposal are to 
- extend  and  clarify  the  scope  of Directive  90/220/EEC  so  that  the  procedures  to  be 
followed are commensurate with the risks; 
- speed  up  the  administrative  procedures. by  early  transmission  of information  and  the 
introduction of a mediation period; 
- strengthen  more  uniform  decision-taking  between  1\fember  States,  based  on  common 
principles for risk assessment; 
- extend the flexibility of Directive 90/220/EEC while maintaining a high level of protection 
for health and the environment and in addition increase transparency, and 
- facilitate the link between the Directive and product legislation. 
3.  :MAIN ELE:MEI\!S OF THE PROPOSAL 
In essence the Commission proposes to: 
- clarify further the scope and the deflllitions within Directive 90/220/EEC; 
- introduce a mandatory monitoring after the placing on the market of products linked to a 
consent granted for a fixed time period.  Since it is very difficult to draw· up, in advance, 
the content of monitoring plans which cover different types  of GMO  (plants,  animals, 
·  mi~ro-organisms), only t4e objectives of the monitoring are defined in.this Proposal.  The' 
specific· post-marketing monitoring plans will be dra'\\'D.  up on·  a case by case basis  and 
carried  out under the control of the relevant Member  State Competent Authority.  The 
objectives of the monitoring are listed in Annex VI(  and the monitoring plan will become 
6 part of  the consent when the relevant Member State Competent Authority has checked that 
the monitoring proposed complies with the provisions of this Annex.  For the renewal of 
the consent, the results of  the monitoring will be reviewed by the Competent Authorities of 
Member States  to  determine ·whether the  existing conditions  and/or monitoring regime 
require modification 
·confums the possibility of  the Commissi~n  to consult any committee it has created ~ith a 
view to advising it on the ethical implications of  biotechnology  on any general matter that 
may rais_e ethical concerns; 
set out principles for the risk assessment under the Directive; 
- classify,  on the  basis  of common  criteria,  experim-ental  releases  and  to  provide  for  a 
distinct administrative procedure for each category of release as  well as for a multi-state 
procedure; 
improve the administrative .procedures and approval system for placing on the market of 
products and introduce siniplified procedures for the renewal of a consent and for cases 
where specific criteria and information requirements on the basis of safety and exp-erience 
have been established; 
- provide for the obligation of formally consulting a Scientific Committee in order to assist 
the Commission in any matt;er which is likely to have an effect on human health and/or the 
environment under the implementation of  Part C of  Directive 90/220/EEC, and 
- increase the transparency ofthe decision-making process by making  ..  available to the public 
the content of the notification for the  placing on the market of  GMOs  as/or in a product, 
the assessment reports carried out for products placed on the market,  the opinion of the 
Scientific Committee(s), and the de_cisions taken under Part B of the Directive; 
- apply  a IIIb  procedure for the regulatory committee to  increase the role of the Member 
States  in  the  decision-making process by giving the  Council the possibility to  reject the 
Commission decision by a simple majority; 
- detail further and broaden labelling requirements on the basis of the broad  ori~ntation for 
an extended Community labelling system for GMO products. 
In addition to  the above-:-mentioned  main modifications,  the  Proposal  contains  amendments 
which were considered necessary in order to ensure consistency and clarity.  Furthermore, it 
was  considered necessary  to  update certain technical parts  of the Directive on the basis  of 
experience and scientific progress. 
The  annexed  table  presents  a  comparison  of the  main  elements  of the  administrative 
procedures in the current Directive 90/220/EEC and the proposed modifications. 
7 4.  CONCLUSIONS 
.  . 
This  Proposal integrates  the  conclusions  of the  1996  Report  on ~e Review of Directive 
90/220/EEC,  takes  account of the recent developments  in  the  area of Biotechnology,  the 
gro':Ving scientific knowledgeas well as. the concern of the general public about the effects of 
genetically. modified ·products ~d  i.ri.corporates  the Commission Policy on Consumer Health 
·and Food Safety,  It should therefore meet the needs and concerns with regard to safety aspects 
for· human health  and  the  environment  The establishment in  this  Proposal of a  common 
methodology to carry out the risk assessment based on independent scientific advice and of 
common objectives for the monitoring  of  genetically modified organisms after they have been 
released constitutes a step f01ward to a more centralised Community system of authorisation. 
In the light of experience, the Commission notes that the existing· IliA Committee procedure is 
not suitable for the authorisations envisaged in the proposed Directive,  In the absence of any 
other  suitable procedure  available within the  framework  of the  decision  of July  1987  on 
Comitology,  it is therefore. appropriate to propose replacing this procedure by that of  the ITIB 
Committee.  Neverthele-ss,  following the mandate of the Amsterdam European Council, the 
Commission  retains  the  option  of amending  this  proposal  in  view  of the  revision  of 
Comitology procedures which it is  required to  present before the end of the first semester 
1998. In addition the Proposal should also provide for sufficient flexibility which will help to 
increase employment potential of this particular fast-growing  sector at the beginning of the 
21st century. 
8 Comparison in a ·tabulated form of the administrative procedures with the main elements in 
current Directive 90/220/EEC and in the Proposal 
A.  Main elements of the Propos.al 
-~ 
Directive 90/220/EEC  Proposal for a modification of Directive 
90/220/EEC 
•  The scope of  the environmental  •  The scope of  the environmental risk 
risk assessment is  assessment was clarified to ·include all direct 
misunderstandable and could be  and indirect environmental aspects; 
considered not to include 
agricultural environment;  confirmation of  the possibility for the 
- • 
•  ethical issues are not specifically  Commission to consider ethical issues 
addressed 
•  Only one standard administrative  •  2 categories of  releases are foreseen: 
procedure for Part B releases  1.  Category I: Releases for which there is 
knowledge and safety (according to the 
criteria set out in Annex V) 
2.  Category II: All other releases 
•  The same administrative procedure  •  Administrative procedures are linked to the 
applies to all  experimental releases  category. 
irrespective of experience.  •  Ca!egory !releases are subject  to a 
Simplification can only be  streamEned procedure while Category II 
introduced if simplified procedures  releases are subject to a standard full 
are adopted by Comitology  procedure which  is similar to the one 
procedure  currently in force. 
,  Introduction of the possibility for multi-state 
releases, both categories. 
$  Introduction of the possibility .for 
experimental releases to be covered by 
specific Community product legislation 
•  No common principles for risk  fl  Annex II introduces for the first time 
assessment  principles for risk assessment. These 
principles apply to all.releases, both 
experimental and placing on the market. 
•  Adoption of simplified procedure  •  The new classification system for 
proven cumbersome and does not  experimental releases as well as the 
ensure rapid adaptation to technical  possibility for multi-state releases will take 
progress  '  into account the experience gained in the 
field and thus streamline the procedures. 
9 A.  Main elements of the Proposal  (  cont'  d) 
•  Cumbersome admiuistrative  •  An improved  administrative 
procedures for the placing on the  procedure for the placing on the 
market of products  market of  products  by immediate 
dissemination of product application 
dossiers to extend the time for 
Member States to consider the 
implications of  the notification,· and 
introduction of a mediation period. 
•  Simplified procedures for the renewal 
of  a consent and for cases where 
specifc criteria and information  -
requirements on the basis of  safety and 
experience have been established. 
•  No obligation to seek independent  •  Obligation to consult the relevant 
scientific advice on controversial  Scientific Committee(s) on any matter 
issues  which is likely to have an effect on 
human health and/or the environment 
before the. Commission initiates the 
Article 21  procedure as required by 
Art 20a 
•  Labelling requirements only on the  •  Labelling provisions according to the 
basis of  safety concerns  Commission labelling policy are 
included 
~ 
•  Lack of  transparency  •  Adaptation to technical ptogress of 
Annexes II - VII and decisions on 
products by Comitology procedure 
IIIb instead of Ilia. 
0  Access of the public to the summary 
of the notification dossier with the 
right to send comments to the 
Commission 
•  Improvement of the labelling 
requirements for products; 
0  Obligatory consultation of the relevant 
Scientific Committee(s) -on issues 
likely to have an effect on human 
health and/or the environment before 
the Commission initiates an Article 21 
procedure; 
0  Publication of the assessment report 
carried out for products placed on the 
market and of the Opinion(s) of  the 
Scientific Committee(s) consulted and 
publication ofthe decisions takeh 
under Part B of the Directive. 
10 A.  Main elements of the Proposal 
•  Restriction of  the scope of  the 
authorisation (time limitation) and . · 
imposing of  monitoring only on the 
· basis of  safety concerns 
(cont'd) 
•  Fixed seven year consent linked to the 
establishment of mandatory 
monitoring 
11 B.  Administrative proc~dures for experimental releases 
I. Standard procedure 
-. 
. ·Current Directive  Proposal for a modification of 
Directive 90/220/EEC 
•  submission of  a technical dossier  •  submission of  a technical dossier 
to a natiodal competent authority  to a national competent authority 
(CA). The dossier must provide all  (CA). The dossier must provide all 
the relevant information as  the relevant information as 
specified in Annex II  specified in Annex III (currently 
•  the CA has to decide on the dossier  Annex II) 
within 90 days. No common  •  the CA has to decide on the dossier 
' 
principles for the risk asse~sment  within 90 days. TheCA has to 
carry out the risk assessment on 
the basis of  the common principles 
•  a summary of  the dossier is  outlined in Annex II 
circulated (SNIF) to the  •  a summary of the dossier (SNIF) is 
Commission within 30 days. The  circulated to the Commission 
Commission  circulates the SNIF  within 30 days. The Commission 
to the CAs of  the other MS  circulates immediately the SNIF to 
the CAs of  the other MS 
•  comments by other MS within 30  •  comments by other MS \Vi thin 3 0 
days  days. All CAs are informed about 
the results of the release submitted 
to  t:1e original CA by the notifier. 
•  the release can only take place if  •  the release can only take place if 
the CA gives its consent  the CA gives its consent 
•  -the original CA circulates to the 
- other CAs the results of the 
release. 
·. 
12 ll. Streamlined procedure( applies only to Category I releases) 
Current Directive  Proposal for a modication of 
Directive 90/220/EEC 
Does not foresee a streamlined  The streamlined procedure is 
procedure. The procedure outlined  applicable to Category I releases 
below is -the standard one that is  which comply with the criteria of 
currently in f?rce.  - AnnexV. 
•  submission of  a technical dossier 
to a national competent authority  •  submission of a technical dossier 
. (CA). The dossier must provide all  to a national competent authority 
the relevant information, as  (CA). The dossier must provide at 
specified in Annex II  least the minillUlm ·amount of 
information from Annex III( 
currently Annexii). The minimum 
amount of information is to be 
decided before the coming into 
force of the Directive. The dossier 
should also supply the information 
Ill  the CA has to decide on the dossier  .  on the basis of  which the 
within 90 days. No common  classification into Category I was 
principles for the risk assessment  made 
•  CA has to decide within 30 days. It 
verifies the classification in 
accordance with  the criteria 
outlined in Annex V. The 
•  a summary of the dossier is  principles for the risk assessment 
circulated (SNl:F) to the  are outlined in Annex II 
Commission \vithin 30 days. The 
Commission  circulates the SNIF  •  the dossier is not circulated to 
to the CAs of the other MS which  other CAs or the Commission. 
have 30 days to  express comments  Every year each Member State 
submits a list with the releases 
•  the release can only take place if  which took place under this 
the CA gives its consent  procedure arid a list of 
notifications that were rejected 
ll  the release can only take place if 
the CA gives its consent 
13 ill. Simplified procedures 
Current Directive  Proposal for a modification of 
.'  Directive 90/220/EEC 
•  The Commission establishes criteri~  Simplified procedures are replaced by the 
for releases which can be carried out  streamlined administrative procedure for 
under simplified procedures  category I GMOs and a multi-state 
(Comitology procedure Illa)  procedure. 
•  If  Member State Authorities consiqer 
that they have obtained sufficient 
experience with releases of  certain  -
GMOs, they may submit proposals for 
simplified procedures to _b~  ~allowed 
for part B releases of  such GMOs 
•  A Decision is taken in accordance 
with Comitology procedure Ilia 
IV. Multi-state procedure 
Current Directive  Proposal for a modification of 
Directive 90/220/EEC 
•  Does not foresee a multi-state  •  Notifier sends dossier to Commission 
procedure.  and CAs of chosen Member States 
where release is requested. 
•  Commission circulates summary of 
the dossier to other CAs. 
•  60 days for other CAs to comment. 
•  Chosen CAs issue individual consents 
within 90 days of receipt of  the 
notification. 
14 c.  ~dministrative procedures for the placing on the market of products 
I.  Main elements 
Current Directive  Proposal for a modification to 
Directive 90/220/EEC 
•  One administrative procedure which  •  One administrative procedure which 
does not involve all MS right from the  involves all MS right from the 
beginning and which has proven to be  beginning and ensures greater 
cumbersome and not very transparent  transparency at all stages and 
simplified administrative procedures 
.  for the renewal of a consent and for  -
cases where specifc criteria and 
information requirements on the basis 
of safety and experience have been 
-
established. 
•  Comitology procedure Ilia 
•  Comitology procedure IIIb 
•  No principles for risk assessment  •  Common principles for risk 
assessment are outlined in Annex II 
•  No obligation to consult a Scientific  •  the relevant Scientific Committee(s) 
Committee on matters likely to have  shall be consulted on issues likely to 
- an effect on human health and/or the  have an effect on human health and/or 
environment  the environment before the 
Commission initiates an Article 21 
procedure 
•  Labelling requirements as provided in  •  Labelling requirements in line with the 
the Commission Directive 97/35/EC  Commission labelling policy are 
included 
•  No obligation to require a  monitoring  •  Introduction of a mandatory 
programme, unless for health and  monitoring programme linked to a 
environmental safety.  consent granted for a limited time 
period; the objectives of  the 
monitoring plan are specified in 
Annex VII 
15 II. Standard procedure 
Current Directive  Proposal for a modification to 
Directive 90/220/EEC 
•  Submission of  a technical dossier to a  •  Submission of  a technical dossier to a 
national CA  national CA. Copy of the dossierto the 
Commission and to all other CAs. 
•  No common principles for risk 
assessment. Examination of  the  •  Common principles for risk 
dossier within 90 days.  · assessment. 
outlined in Annex II. Examination of 
the  dossier within 90  -
•  In case of a favourable opinion, the  days and preparation of an assessment 
dossier is circulated to the  report 
Commission and via  th~ Commission 
to all other CAs which have 60 days to  •  Submission of  the assessment report to 
express comments or raise objections.  the Commission which circulates it to 
The original CA has no obligation to  the other CAs. Other CAs and the 
submit a detailed ·assessment of  the  Commission have 30 days to submit 
dossier. The Commission has no  comments or raise objections 
possibility for comments or objections 
•  In case of  objections,Comitology  . 
procedure rna has to be followed  •  In case of  objections, total of 60 days 
from submission date to resolve 
disagreements.  If, at the end of this 
period, there is no agreement or if the 
assessment report states that there is 
additional assessment required, 
Comitology procedure IIIb has to be 
followed 
•  In the absence of objections, consent 
shpuld be granted by the original CA  •  In the absence of  objections, consent 
and the product may circulate freely  should be granted by the original CA 
throughout the Community  and the product may circulate freely 
throughout the Community 
0  In any case, tl:J.e consent is granted for 
a time period of seven years and 
linked to a mandatory monitoring after 
the placing on the market; 
o No obligation to formally consult (a)  o Obligation to consult  the relevant 
Scientific Committee(s)  Scientific Committee(s) on any aspects 
which is likely to have an effect.on 
human health and/or the environment 
before the Commission initiates an 
Article 21  procedure 
l6 '  .. m. Simplified procedure for cases where specifc criteria and information requirements on 
the  ·basis of safety and experience h~ve  been established 
.  Current Directive  Proposal for amodification to 
'  Directive ·90/220/EEC 
•  Does not foresee a simplified  • For Part C releases where specific 
procedure.  criteria and information requirements 
on the basis of safety and· experience 
have been established, submission of  a 
technical dossier to the lead CA. CA 
considers within 15 days whether  -
/ 
application meets the requirements for 
the simplified procedure. If  no, 
application is rejected .  . 
If  yes, CA circulates it to the  • 
' 
Commission and the CAs of  the other 
MS. 
•  Comments/objections within 30 days . 
•  Total of  45 days from submission date 
to resolve disagreements. 
•  If, at the end of this period, there is no 
agreement, Comitology procedure IIIb 
has to be followed 
•  In the absence of objections, consent 
issued by the lead CA within 15 days. 
IV. Simplified procedure for the renew-al of a consent 
Current Directive  Proposal for a modification to 
Directive 90/220/EEC 
•  ·Does not foresee a simplified  •  In the case of the renewal ofa consent, 
procedure.  submission of a technical dossier to 
the Commission. Commission 
circulates it to the CAs of all MS. 
•  Comments/objections within 30 days  . 
•  Total of 45 days from submission date 
to resolve disagreements. 
•  If, at the end of this period, there is no 
agreement, Comitology procedure liTh 
has to be followed 
•  In the absence of objections, consent 
issued by the lead CA responsible for 
the previous consent. 
17 Proposal for a 
ElJROPE.A..:.~ PARLL<\tv!ENT A.!.'-.'D COlliCIL DIRECTIVE 
2.Illending 
DIRECTIVE 90/220/EEC 
on the deliberate release into the environment of genetically modifie~ organisms THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION, 
Having ~egard to the Treaty establishing the European Community, and in particular Article lOOa 
thereof; 
Having regard to the proposal from the Commission
5 
; 
Having regard to the opinion of  the Economic and Social Committee
6
; 
Acting in accordance with the procedure laid down in Article 189b of the Treaty 
7 
; 
Whereas, under the Treaty, action by the Community relating to the environment should be based 
on the principle that preventive action should be taken; 
Whereas, the Report of the Commission on the Review
8 of Council Directive 90/220/EEC
9 
,  as last 
amended  by  Commission  Directive  97/35/EC
10 
,  adopted  on  10  December  1996,  identified  a 
number of areas where improvement is needed; 
Whereas there is a need for clarification of the scope of  the Directive and of  the definitions thereof; 
Whereas deliberate releases of GMOs into the environment carried out for experimental purposes or 
for any other purposes than placing on the market can now be classified in two categories on the 
basis of common  criteria and  whereas  it is  appropriate to  foresee  different procedures for  each 
category; 
Whereas the provisions of the Directive concerning Part B releases of products shall not apply to 
products· under  development  covered  by  Community  legislation  which  provides  for  a  specific 
environmental risk assessment similar to that laid down in this Directive; 
Whereas it is  necessary to  introduce in this Directive the obligation to carry out a monitoring in 
order  to  trace  any  direct  or  indirect,  immediate  or  delayed  effects  on human  health  and  the 
environment of GMOs as or in products after they have been placed on the market; 
Whereas it is  appropriate that the administrative procedure for granting consents to the placing on . 
the market of GMOs as or in products should become more efficient and more transparent and that 
consent should only be granted for a  fixed period; 
Whereas it is appropriate to introduce a simplified administrative procedure for granting consents to 
the placing on the market of products in cases where specific criteria and information requirements . 
on the basis of  safety and experience have been established; 
Whereas for products for which consent has been granted for a fixed period a simplified procedure 
should be applicable for the renewal of  the consent; 
6 
7 
8 
9 
10 
COM(96)630 
OJ N° Lll7,8.5.1990,p.15 
OJ No L169,27.6.1997,p.72 
18 Whereas· there is a need for consultation of the relevant Scientific Committee(s) established by the 
Commission Decision 97/579/EC
11  on matters which are likely to have an impact on human health 
and/or the environment; 
Whereas the content of the present Directive-has  duly taken into account international experience 
and international trade commitments in, this field; 
Whereas the Commission may consult any committee it has created with a view to advising it on 
the ethical implications of biotechnology on general matters which in the view of the Commission 
may raise ethical concerns; 
Whereas  establishing  a  common  methodology  to  carry  out  the  risk  assessment  based  on 
independent scientific advice and  common objectives for the monitoring of genetically modified 
organisms after their release, constitutes a step forward to a more centralised Community system of 
authorisation; 
Whereas pending the implementation of such a system,  it is  appropriate to  give the Council the 
possibility to reject the Commission decision by simple majority; 
'Whereas  the provisions  of this  Directive  apply  without prejudice  to  the  provisions  of Council 
Regulation  (EEC)  N°  339/93  of 8 February  1993  on  checks for  conformity with the  rules  on 
product safety in the case of  products imported from third countries
12 
;  · 
Whereas  prod~cts containing and/or consisting of genetically modified organisms covered by this 
Directive cannot be imported into the Community if  they do not coinply with the provisions of this 
Directive;  -
Whereas the .monitoring foreseen under the provisions  of this  Directive is  complementary to  the 
monitoring foreseen under specific product legislation; 
'Whereas  in  order to  increase  the  effective implementation  of the  provisions  adopted under this 
Directive· it is appropriate to provide for sanctions to be applied by Member States, 
11  -
OJN° L237, 28.8.1997,p.l8 
OJWL40, l7.2.I993,p.I 
12 
19 HAS ADOPTED TillS DIRECTIVE: 
Article 1 
Directive.90/220/EEC is amended as follows: 
1. Articles 1 to 6 are replaced by the following: 
· "Article 1 
1.  The  objective of this  Directive  is  to  approximate  the  laws,  regulations  and  a-dministrative 
provisions  of the  Member  States  and  to  protect  human  health  and  the  environment when 
carrying out the deliberate release of  genetically modified organisms into the environment 
a)  for research and development purposes or for any other purposes other than placing 
on  the market 
b) for placing on the market of genetically modified organisms as orin products. 
2.  This Directive shall not apply to the carriage of genetically modified organisms by rail, road, 
inland waterway, sea or  air. 
Article 2 
For the purposes of  this Directive: 
1.  'organism' is any biological entity capable of  replication or of transferring genetic material; 
2.  'genetically modified organism (GMO)' means  an  organism in which the genetic material has 
been altered in a \Vay that does not occur naturally by mating and/or natural recombination. 
Within the terms of this definition: 
a)  genetic modification occurs  at least through the use of the techniques  listed in Annex I A 
Part 1;  -
b) the techniques listed in Annex I A Part 2 are not considered to result in genetic 
modification; 
3.  'deliberate release'  means  any  intentional  introduction  into  the  environment of a  GMO  or  a 
combination  of GMOs  without provisions  for  containment  such  as  physical  barriers,  or  a 
combination of physical barriers together with chemical and/or biological barriers used to  limit 
thei~ contact with the gener~l population and the environment~ 
4.  'placing on the market' means supplying or making available to third parties. 
20 5.  'notification' means the presentation of documents  containing the requisite information to. the 
competent authority of a Member State. TP.e person making the presentation shall be referred to 
as 'the notifier'; 
6.  'environmental risk assessment' means the evaluation of the direct and indirect risks to human 
health· and the environmentwhich the deliberate release of GMOs  into  the  environment may 
pose. 
Article 3 
This Directive shall not apply to organisms obtained through the techniques of  genetic modification 
'  •  1  . 
listed in Annex I B. 
Article 4 
1.  Member States shall ensure that all appropriate measures are taken to avoid adverse effects on 
human health and the environment which might arise from the deliberate release of GMOs. To 
this end GMOs may only be deliberately released into the environment following an assessment 
of any potential risks for human health and/or the environment in conformity with part B or part 
C of this Directive. The risk assessment shall take account of  the principles laid down in Annex 
11. 
2.  Member States shall designate the competent authority~r authorities responsible for carrying out 
the requirements of  this Directive and its Annexes. 
3. Member States shall ensure that the competent authority organizes inspections and other control 
measures as appropriate, to ensure compliance with this Directive. 
PARTB 
Deliberate release of GMOs into the environment for research and development purposes or for any 
other purpose than for placing on the  market 
Article 5 
Articles  6  to  9  shall  not  apply  to  any  products  under  development  covered  by  Community 
legislation which provides for a specific environmental risk assessment similar to that laid down in 
those articles. 
Article 6· 
1.  Any person, before submitting a notification under Articles 6a, 6b and· 6c concerning the release 
of a GMO or of a combination of  GMOs for the purpose of research and development, or for any 
other purpose than for placing on the market, shalt carry out a risk assessment of the deliberate 
release of GMOs as  regards the risks to human health and/or the environment that may occur, 
21 taking due account of the information which may be necessary for evaluating any potential risks, 
whether immediate or delayed,  which the release may  present· for  human health  and/or. the 
environment. This information is laid down in Annex ill.  .  . 
2 .. Deliberate releases which fall under this part are classified in 2 categories: 
Category  I:  Deliberate releases of GMOs which comply with the criteria set out in Annex v 
parts A orB  -
Category II: All other·releases." 
2.  The following articles 6a to 6d are inserted: 
"Article 6a 
1.  Any person before undertaking a Category I deliberate release of a GMO or of a combination of 
GMOs, shall submit a notification to the competent authority referred to in Article 4(2) of the 
Member State within whose territory the release is to take plac'e.  . 
2. The notification referred to in paragraph 1 shall include: 
a technical dossier  supplying the information on the basis of which the classification of the 
deliberate release \Vas  made. The notification referred to in paragraph 1 shall include a technical 
dossier  supplying  the  information  specified  in  Annex  III  necessary  for  evaluating  any 
foreseeable risks from the deliberate release of a GMO or combination of GMOs, in particular: 
a)  information relating to the GMO(s), 
b)  information relating to the conditions of release and the receiving environment, 
c)  information on the interactions between the GMO(s) and the environment, 
d)  a statement evaluating the impacts and risks posed by the GMO(s) to human health or 
the environment from the uses envisaged; 
3.  The competent authority shall verify the classification into  Category I  in accordance with the 
criteria referred to  in Article 6(2) and shall examine the dossier for any potential risks to human 
health and/or the environment. The competent authority shall respond in writing to the notifier 
within 30 days of receipt of the notification by either: 
a)  indicating that it is satisfied that the notification is in compliance with this Directive and that 
the release may proceed, or 
b)  indicating that the release does not fulfil the conditions of this Directive and the notification 
is therefore rejected. 
4.  Before this Directive is  implemented,  the Commission shall  establish in accordance with the 
procedure laid do\vn in Article 21  the minimum amount of technical information from Annex III 
to be included in the dossier referred to in paragraph 2. 
22 Article 6b 
1.  Any person before undertaking a Category II deliberate release of a  GMO or of a combination of 
GMOs, must submit a notification. to the competent authority referred to in Article 4{2) of the 
Member State within whose territory the release is to take place. 
.  i 
2.  The  notification referred  to  in paragraph  1 shall  include a  technical  dossier  supplying  the 
infortnation  specified  in Annex  III  necessary  for  evaluating  any  foreseeable  risks  from  the 
deliberate release of  a GMO or combination of  GMOs, in particular: 
a)  general information including information on perso.nnel and training, 
b) information relating to the GMO(s  ), 
c)  information relating to the conditions of  release and the receiving environment, _ 
'  ' 
d) information on the interactions between the GMO(s) and the environment, 
e)  information on monitoring, control, waste treatment and emergency response plans; 
f)  a statement evaluat~g  .t?e impacts and risks posed by the GMO(s) to human health or the 
environment from the uses envisaged;  · 
3.  The  competent  authority,  having  considered,  where  appropriate,  any  observations  by  other 
Member States made in accordance with Article 9, shall respond in writing to the notifier within 
90 days of  receipt of  the notification by either: 
a)  indicating that it is satisfied that the notification is in compliance with this Directive and that 
the release may proceed, or 
b)  indicating that the release does not fulfil the conditions of this Directive and the notification 
is therefore rejected. 
4.  For the purpose of calculating the 90-day period referred to  iii paragraph 3, any periods of time 
during which the competent authority: 
a)  is awaiting further information \vhich it may have requested from the notifier, 
or 
b)  is carrying out a public inquiry or consultation in accordance with Article 7 
shall not be taken into account. 
5.  The notifier may proceed with the release only when he has received the written consent of the 
competent authority, and in conformity with any conditions required in this consent 
Article 6c 
1.  In the case of partB releases planned to take place in more than one Member State, the applicant 
may choose to follow the procedure outlined in the following paragraphs. 
2.  A notification shall  be  submitted to  the Commission and  to  the  competent authorities  of the 
Member States where the release is to be carried out. The notification shall include a technical 
dossier supplying the information outlined in Article 6a(2) for deliberate releases under category 
I or Article 6b(2) for all other releases together with a summary of the technical dossier. 
23 3.  Upon receipt of  the notification the. Commission shall forward the summary of  the dossier to the 
competent authorities of those Member States which have not received the full  dossier.  The 
competent authorities may forward comments within 60 day$ of  receipt of  the notification to the 
Commission.  The Commission may immediately  forward  these  comm:ents  to  the  competent 
authorities referred to in paragraph 2.  · 
4.  The notifier shall submit any additional information which may have been requested by one of 
the· competent authorities  referred  to  in paragraph  2  to  the  Commission  and  all  the  other 
competent authorities referred to in paragraph 2. 
5.  The competent authorities referred to in paragraph 2, having considered any comments by other 
competent authori~ies, shall respond in writing to the notifier within 90 days of receipt of the 
notification by either: 
a)  indicating that it is satisfied that the notification is in compliance with this Directive and that 
the release may proceed on their territory or 
b) indicating that the release does  not fulfil the  conditions of this  Directive and the release 
cannot take place on their territory. 
6.  For the purpose of calculating the 90-day period referred to  in paragraph 5, any periods of time 
during which the competent authorities 
a)  are awaiting further information which it may have requested from the notifier, 
or 
b) are carrying out a public inquiry or consultation in accordance with Article 7 
shall not be taken into account. 
Article 6d 
1.  In the event. of any  modification of the deliberate  release of GMOs  or of a  combination  of 
GMOs which could have consequences with regard to potential risks for human health or the 
environment  or  i£'  :-:ew  information  has  become  available  on  such  risks,  either  while  the 
notification  is  being  examined  by the  competent  authority  of a  Member  State or  after  that 
authority has given its written consent, the notifier shall immediately: 
a)  revise the measures specified in the notification, 
b) revise the measures specified in the notification, inform the competent authority in advance of 
any modification or as soon as the new information is available, 
c)  take the measures necessary to protect human health and the enviropment · 
2.  If information becomes  available subsequently to the competent authority  which could  have 
significant consequences for the risks posed by the release, the competent authority may require 
the notifter to modify the conditions of, suspend orterminate the deliberate release." 
24 3. Articles 9 to 13 are replaced by the following: 
"Article 9 
1.  The  competent  authorities  shall  s~nd to  the  Commission,  within  30  days  of its  receipt,  a· 
summary of  each Category II  notification received under Article 6b. The format of  this sum.niary 
will be established by the Commission in accordance with .the procedure laid down in Article 21. 
2.  The Commission shall immediately forward these summaries to the other Member States, which 
may, within 30 days, present observations through the Commission or directly. 
3.  The competent authorities shall inform the other Member States  and the Commission of the 
· final decisions taken in compliance with Article 6b(3) and 6c(  5) and of  the results of the releases 
received in accordance with Article 8. 
4.  Once a year Member States shall send to the Commission and the competent authorities of the 
other .Member States a list of GMOs which have been released on their territory in accordance 
with Article 6a(3)(a) and ·a  list of notifications that were rejected  in accordance with Article 
6a(3)(b). 
PARTC 
Placing on the market of  products containing GMOs 
Article 10 
1.  Articles 11  to  18  shall  not  apply  to  any  products  covered  by  Community  legislation  which 
provid~s for a specific environmental risk assessment similar to that laid down in this Directive. 
Article 11 
1.  Before· a  GMO  or a  combination of GMOs  are  placed  on  the  market  as  or in  a  product,  a 
notification shall  be submitted to  the competent authority of the Member State where such  a 
product is  to  be placed on the market for the first time.  Upon receipt of the notification the 
competent authority shall" without delay forward a copy of the notification to the Commission 
and to the competent authorities of  the other Member States. 
2.  The notification shall contain: 
a)  the information required in Annexes- III and IV.  This information shall take into account the 
diversity of sites  of use of the  product and  shall  include  information on data  and  results 
obtained from research and developmental releases concerning the impact of the release on 
human health and/or the environment; 
25 b) an assessment of any risks for human health and/or the environment related to the GMOs or 
the combination of GMOs contained in the product, taking due account of the principles laid 
down in Annex II; 
c)  the conditions for the placing on the. market of the product, including specific conditions of 
use ·and handling; 
d)  a detailed plan for monitoring in order to identify any relevant direct, indirect, immediate or 
delayed effects of the GMOs on human health and/or the environment in accordance with the 
requirements outlined in Annex VII; 
e)  a proposal for labelling which shall comply with the requirements laid down in Annex IV an:d 
which shall inform the consumer of  the _presence of  GMOs in the product(s) whenever there is 
evidence that the product(s) cbntain(s) GMOs. 
f)  a proposal for packaging which shall comprise the requirements laid down in Annex IV. 
If on  the basis  of the results  of any  release notified  under  Part B  of this  Directive,  or on 
substantive, reasoned scientific grounds, a notifier considers that the placing on the market and 
use of a product do not pose a risk to human health and the environment, he may propose not to 
comply with one or more of  the requirements of  Annex IVB. 
3.  The notification shall also include a summary ofthe dossier. The format of the summary shall be 
established in accordance with the procedure laid down in Article 21. 
4.  The notifier shall include in this notification information on data or results from releases of the 
same GMOs or the same combination of GMOs previously or currently notified and/or carried 
out by the notifier either inside or outside the Community. 
5.  The notifier may  also  refer to  data or results from  notifications  previously submitted by other 
notifiers, provided that the latter have given their agreement in writing. 
· 6.  In order for a GMO or combination of GMOs to  be used for  a use different than that already 
specified in a notification, a separate notification shall be submitted. 
Article 12 
1.  On receipt and after acknowledgement of the notification referred to in Article 11, the competent 
authority shall examine it for compliance with this DirectiYe. 
2.  At the latest 90 days after receipt of the notification, the competent authority shall forward to the 
Commission its assessment report. 
3.  The assessment report shall indicate whether the GMO(s)  in  question should be placed on the 
market and under which conditions, if any, or whether additional assessment is required. 
The  assessment  reports  shall  be  established  in  accordance  with  the  guidelines  laid  down  in 
Annex VI. 
26 ·  4.  For the purpose of  calculating the 90-day period referred to ill paragraph 2, any periods of time 
·during  which  the  competent  authority  is  awaiting  further  iilformation  which  it  may  have 
requested .from  the  notifier shall  not be taken· into_  account.  The  competent authority shall 
motivate  any request for further information.  It shall  inform  the  Co1D11fission  and  the  other 
competent authorities of  any additional information submitted by the notifier. 
Article 13 
1.  On  receipt  of the  assessment  report  referred  to  in  Article 12(2),  the  Commission  shall 
immediately forward it to the competent authorities of  all Member States. 
2.  In the case of a favourable assessment by the competent authority referred to in paragraph 1,  a 
competent authority designated under Article 4(2)  or the Commission may make comments or 
present reasoned objections to  the placing on the market of the  GMO(s) in question within a 
period of  3 0 days from the date of  circulation of  the assessment report by the Commission.  · 
Comments or objections of competent authorities and replies by the notifier shall be forwarded 
to the Commission which shall immediately circulate them to all competent authorities. 
The Competent Authorities and the Commission may discuss  any  outstanding issues with the 
aim of arriving at an agreement within 60 days from the date of circulation of the assessment 
report. 
3.  In the absence of any reasoned objection from another Member State or the Commission within 
30 days following the date of distribution of the assessment report or if possible outstanding 
issues are resolved within the 60 day period referred to in paragraph 2, the competent authority 
that had originally received and assessed the dossier shall give its  consent in writing within 30 
days so that the product can be placed on the market and shall inform the other Member States 
and the Commission thereof." 
4.  The following .Articles 13a to 13e are inserted: 
"Article 13a 
1.  Byway of derogation from the procedures outlined in Articles 11,  12,  13  and 13c, the procedure 
laid  down  in  Article  13b  shall  apply  to  GMOs  which  meet  the  criteria  and  information 
requirements established according to the following procedure. 
2.  The Commission, on its own initiative or on the proposal of a competent authority, may adopt 
criteria and  information requirements  to  be met for the notitlcation of deliberate releases for 
pla~ing on the market of certain types of GMOs as or in products under the simplified procedure 
laid  down  in  Article  13b,  after  consultation  of the  relevant  Scientific  Committee(s),  in 
accordance  with  the  procedure  laid  down  in  Article  21.  The  criteria 'and  the  information 
requirements  shall  be  bas~d on safety to  human  health  and/or  the  environment and  on the 
scientific evidence available on such safety and  on the experience  gained .with the release of 
comparable GMOs. 
27 '3.  Before the  decision  procedure in accordance with Article  21  on a  decision  for.  criteria  and 
information requirements referred  to  in paragraph 2 is  initiated,  the Commission shall make 
available to the public this proposal. The public may make comments within 60 days. 
.  . 
Article 13b 
I.  For GMOs for which the criteria and information requirements have been laid down according 
to Article 13a(2), the notifier shall submit a notification including a summary of the dossier to 
the competent authority of the Member States where the product is to be placed on the market 
for the first time. 
2.  The competent authority shall respond in writing to the notifier within 15  days of receipt of the 
notification by either: 
a)  indicating  that  the  notification  is  in  compliance  with  the  critieria  and  information 
requirements established according to ArtiCle 13a and that the notification is accepted to be dealt 
with under the simplified procedure or . ·  · 
b)  indicating  that  the  notification  does  not  fulfil  the  conditions  for  the  application  of the 
simplified procedure and that the notification is rejected. 
3.  In  the  case  where  the  notification  is  rejected  the  competent  authority  shall  inform  the 
Commission and the competent authorities of  the other Member States thereof. 
4.  In case.s where the  notificatio~ is  accepted to  be dealt with under the simplified procedure, the 
competent authority shall circulate the notification dossier to the Commission and the competent 
authorities of the other Member States without delay. Upon receipt the Commission shall make 
available to the public the summary of  the notification dossier. 
5.  The  competent  authorities  or  the  Commission  may  make  comments  or  present  reasoned 
objections to the placing on the market of the GMO(s)  in  question within a period of 30 days 
from the date of circulation of the notification dossier. The comments or objections and replies 
by the notifier shall be forwarded to the Commission which shall immediately circulate them to 
all  competent authorities.  The  Competent Authorities  and  the  Commission  may  discuss  any 
outstanding issues with the aim of arriving at an  agreement within 45  days  from  the  date  of 
circulation of the notification. 
· 6.  In the absence of any reasoned objection from  a competent authority of a Member State or the 
Commission within 30 days  following the date of circulation of the notification dossier  or if 
possible outstanding issues are resolved within the 45  day period referred to  in paragraph 5, the 
competent authority that received the original notification shall give its consent in writing within 
15  days so that the product can be placed on the market and shall inform the Commission and 
the competent authorities of  the other Member States thereof. The consent shall be granted for a 
fixed period of seven years. 
Article 13c 
1.  By way pf derogation from the procedure outlined in Article  11,  12, .13  and  13b the following 
procedure shall apply to the renewal of  the consent. 
28 2. ·The notifier shall submit at the latest 12 months before the end of the consent a notification to 
the Commission which shall con~  in particular 
' 
a)  a copy-of the consent to the placing on the market of  the GMOs, 
b) a report on the results of  the monitoring which was carried out according to Article 13e(2) 
~d  . 
c)  any other new information which has become available with regard-to the risks of  the product 
to human health and/or the environment. 
J. On receipt of the notification referred to  in paragraph 2,  the  Commission shall immediately 
forward it to the Competent Authorities of  all Member States.  . 
Comments  or reasoned  objections  to  the  renewal  of the  consent  shall  be forwarded  to  the 
Commission within 30 days from the. date of submission of the notification.  The Commission 
shall without delay circl.)la~~ any comments or objections to all competent authorities. 
The  competent  authorities  of the  Member  States  and  the  Commission. may  discuss  any 
outstanding  issues  with the  aim  of arriving  at  an  agreement  within  45  days  following  the 
circulation of  the notification. 
4.  In the absence of ~y  reasoned objection from  a Member State or the Commission within.30 
days following the date of submission referred to  in paragraph 3, the competent authority that 
received the original notification shall give its consent in writing for the renewal of  the briginill 
consent and  shall inform the other Member States  and  the  Commission thereof.  The consent 
shall be granted for a fixed period of seven years. 
5.  Following a notification for the renewal of a consent in accordance with paragraph 2, the notifier 
may continue to place .the GMOs on the market under the conditions specified in that consent 
until a final decision has ·been taken on the renewal of  the consent. 
Article 13d 
1.  In cases where an objection is raised and maintained in accordance with Article 13(2), 13b(5) or 
13c(3), or an additional assessment is required in accordance with Article 12(3), the Commission 
shall  take  a  decision  within  three  months  in  accordance  with  the  procedure  laid  down  in 
Article 21. 
For the purpose of calculating the three month  period,  any  period  of time during which the 
Commission is awaiting further information which it may have requested from. the notifier or is 
seeking the opinion of a Scientific Committee which has been consulted shall not be taken into 
account. 
2.  Where the Commission has taken a :favourable decision,  the competent authority that received 
the original notification shall give, within 30 days following the publication of the Commission 
decision, consent in writing to the notification so that the product may be placed on the market 
for the perio,d of seven years  and  shall inform the other Member States ~d  the Commission 
thereof  .. 
29 Article 13e 
1.  Once  a  product has  received  a  written consent,  it may be used without further notification 
throughout the Community in so .far as  the specific conditions of use and the environments 
and/or geographical areas stipulated in these conditions are strictly adhered to. 
2.  Followin~ the placing on the market of  (a) GMO(s) as or in a product, notifier(s) shall carry out 
monitoring accorqing to the plan referred to in Article 11(2) and the conditions specified in the 
consent.  Regular  reports  of this  monitoring shall  be submitted  to  the  Commission and  the 
competent authorities of  Member States. 
3.  Consent to the placing on the market of GMOs in or as  a product shall be granted for a  fixed 
period of  seven years. The notifier may proceed with the placing on the market  ·only when he 
has received the written consent of the competent authority in acCordance with Articles 13,  13b, 
13c  and Bd,  and  in  conformity  with  any  conditions,  including  reference  to  particular 
ecosystems/environments, required in that consent. 
4.  If new information has become available with regard to the risks of the product to human health 
or the environment, either before or after the written consent, the notifier shall immediately: 
a)  revise the information and conditions specified in the notification dossier, 
b)  ·inform the competent authority, and 
c)  t~e  the measures necessary to protect human health and the environment 
5.  If th¢  c0mpetent authority  receives  additional  information  pursuant to  paragraph 4,  it  shall 
immediately inform the Commission and the competent authorities of the other Member States. 
6.  Member States shall take all necessary measures to ensure that users comply with the conditions 
of use specified in the written consent." 
5.  Article 14 is.replaced by the following: 
"Article 14 
Member  States  shall  take all  necessary  measures  to  ensure that the  labelling  and  packaging  of 
products containing, or consisting of, GMOs comply with relevant proposal in the dossier and with 
the  relevant requirements  specified  in the written  consent referred  to  in Articles 13(3),  13b(6), 
13c(4) or 13d(2)." 
6.  In Article 15  the words "a deliberate release" are replaced by "the placing on the market". 
7.  Articles 16,  17 and  18 are replaced by the following: 
30 "Article 16 
1.  Where a Member State, as a resulfof  new information or reassessment of"existing information, 
has detailed grounds for considering that a product which has been properly notified and has 
received  written  consent  under  this  Directive  constitutes  a  risk  to  human  health  or  the 
environment,  that Member State  may provisionally restrict or prohibit the use and/or sale of  that 
product on its territory.  It shall immediately inform the Commission and the other Member 
States of  such action and give reasons for its deCision. 
2.  A decision shall be taken on the matter within three months in accordance with the procedure 
laid down in Article 21. 
Article 17 
1.  Wi1:hout prejudice to  A.ft~<?~e 19, upon receipt of a notification in accordance with Article 11 (I) 
the Commission shall immediately make available to the public the summary referred  to  in 
Article  11(3).  The  public  may  make  comments  within  30  days.  The  Commission  shall 
immediately forward the comments to all competent authorities of  the Member States. 
/ 
2.  Without prejudice to Article 19, all GMOs which have received written consent for the placing 
on the  market or whose  placing on the  market was  rejected  as or in  products  under  this 
Directive, the assessment reports carried out for these GMOs· and the opinion(s) of  the Scientific 
Committees consulted shall be made available to  the public.  For each product,  the GMO or 
GMOs contained therein and the use or uses shall be clearly specified. 
3.  \Vithout prejudice to Article 19, upon receipt the Commission shall maRe available to the public 
the information referred to in Article 9(3) and (4). · 
Article 18 
1.  Member States shall send to the Commission, at the end of each year, a brief factual report on 
the their experience with the GMOs placed on the market in or as products under this Directive. 
2.  The Commission shall send to  the European Parliament and  the Council,  every three years,  a 
report  on  the  experience  of Member  States  with  GMOs  placed  on  the  market  under  this 
Directive. 
3.  \Vhen submitting this report for the first time, the Commission shall at the same time submit a 
specific report on the operation of this Part of  this Directive including an assessment of all its 
implications." 
8.  In Article 19 paragraph 4 the words "Articles 5 or 11" are replaced by "Articles 6a, 6b, 6c, 6d, 
11,  13b or 13c". 
31 9.  Article 20 is replaced by the following: 
"Article 20 
According to the procedure laid down in Article 21, the Commission shall adapt Annexes IT to VII 
to technical progress." 
10.  The following Article 20a is inserted. 
"Article 20a 
The relevant  Scientific. Committee(s) shall be consulted by the Commission on any matter which is 
likely to have an effect on human health and/or the environment' before the decision procedure 
referred to in  Articles 13d(l) or 16(2) is initiated." 
11.  Article 21  is replaced_ by the following: 
"Article 21 
Where the procedure defined in this Article is to be implemented, the Commission shall be assisted 
by  a  committee  composed  of the  representatives  of the  1\fember  States  and  chaired  by  the 
representative of  the Commission, here~after referred to as the 'Committee'. 
The representative of the Commission shall submit to the committee a draft of the measures to be 
taken. The Committee shall deliver its opinion on the draft within a time limit which the Chairman 
may  lay  down  according  to  the urgency  of the  matter.  The  opinion  shall  be delivered  by  the 
majority laid  down in  Article 148  (2) of the Treaty in the case of decisions which the Council  is 
required to  adopt on  a proposal from  the  Commission.  The  votes  of the  representatives  of the 
Member States tvithin the committee shall be weighted in the  manner set out in that Article.  The 
Chairman shall not vote. 
The Commission shall adopt the measures envisaged if they are in accordance with the opinion of 
the Committee. 
If the measures envisaged are not in accordance with the opinion of the Committee, or if no opinion 
is  delivered, the Commission shall, without delay, submit to the Council a proposal relating to the 
measures to be taken. The Council shall act by a qualified majority. 
If, on the expiry of a period of three montbs from the date of referral to the Council, the Council 
has not acted, the proposed measures shall be adopted by the Commissi'Jn, save where the Council 
has decided against the said measures by a simple majority."  · 
32 12.  The following articles 22a and 22b are inserted: 
"ArtiCle 22a 
Member States shall determine the sanction arrangements applicable to violations of the national 
provisiops  made  pursuant  to  this  D~ective,  and  take  any  measure  necessary  to  ensure  their 
implementation.  The  sanctions  thus · envisaged  must  be  effective,  proportional  and  dissuasive. 
Member States  must notify these provisions to  the Commission at the latest by ......... [the  date 
mentioned in Article 2], and any later modification concerning them as soon as possible. 
Article 22b 
Before .......... [a date seven years after the dateforseen for the transposition according to Article 2], 
the consents granted for placing on the market of  products containing or consisting of GMOs. before 
........... [the date mentioned in Article 2]  shall be renewed according to  the procedure outlined in 
Article 13 c." 
13.  The Annexes are replaced by the Annexes to this Directive.  ~ 
Article2 
Member States shall bring into force the laws, regulations and administrative provisions ·necessary 
to  comply  with  this  Directive· not  later  than  ....................  They  shall  forthwith  inform  the 
Commission thereof. 
\Vhen these measures are adopted by Member States, they shall contain a reference to this Directive 
or  shall  be  accompanied  by  such  reference  on  the  occasion  of their  official  publication.  The 
methods of making such a reference shall be laid down by the l\fember States. 
Article 3 
This Directive shq.ll enter into force on the 20th day following tha:t of its  publication in the Official 
Journal of the European Communities. 
Article 4 
This Directive is addressed to the Member States. 
Done at .................... . 
F9r the European Parliament 
The President 
33 
For the Council 
The President Annexes 
ANNEX! A 
TECHNIQUES REFERRED TO IN ARTICLE2 (2) 
PART 1 
Techniques of  genetic modification referred to in Art~cle 2 (2) (a) are inter alia: 
(1)  recombinant nucleic acid techniques involving the formation of new combinations of genetic 
material by the insertion of nucleic acid  molecules produced by whatever means outside an 
organism, into any virus, bacterial plasmid or other vector system ari.d their incorporation into a 
host organism in which they do not naturally occur but in which they are capable of continued 
propagation; 
(2)  techniques involving the direct introduction into  an organism of·heritable material prepared 
outside the organism including micro-injection, macro-injection and micro-encapsulation; 
(3)  cell. fusion (including protoplast fusion) or hybridisation techniques where live cells with new 
combinations of heritable genetic material are formed through the fusion of two or more cells 
by means of methods that do not occur naturally. 
PART2 
Techniques  referred  to  in  Article 2 (2) (b)  which  are  not  considered  to  result  in  genetic 
modification, on condition that they do  not involve the use of recombinant nucleic acid molecules 
or  genetically modified  organisms  made  by  techniques/methods  other  than  those  excluded  by 
Annex IB: 
( 1)  in vitro fertilization, 
(2)  natural processes such as:  conjugation, transduction, transformation, 
(3)  polyploidy induction. 
34 ANNEXIB 
TECHNIQUES REFERRED TO IN ARTICLE 3 
. Techniques/methods of  genetic modification yielding organisms to be excluded from the Directive, 
on the  condition  that they  do  not involve  the  use  of recombinant  nucleic  acid  molecules  or 
genetically  modified  organisms  other  than  those  produced  by  one  or  more  of  the 
techniques/methods listed below are: 
(1)  mutagenesis, 
(2)  cell fusion (including protoplast fusion) of  plant cells \Vhere the resulting organisms can also be 
produced by traditional breeding methods. 
35 ANNEX II 
Principles for the environmental risk assessment 
A. The environmental risk assessment referred to in Articles 6 and  11  shall take into account the 
following: 
1. Elements which may be considered as potentially harmful effects 
pathogenicity to humans, animals or plants 
compromising of  prophylactic or therapeutic treatments 
effects on population dynamics within the receiving environment 
effects on geochemistry  . 
the uncontrolled spread of  the GMO(s) in the environment and invasion of  unrelated 
ecosystems  . 
effects resulting from the transfer of  the inserted genetic material to other  orgarusms 
phenotypic and genetic instability 
2.  Elements which.form the basis of the risk assessment: 
the characteristics of  the non-modified organism(s) and of  the 
introduced trait(s) which give fise to the GMO(s); 
the characteristics of  the intended use; 
the receiving environment, and 
the interaction between these 
Information  from  releases  of similar  organisms  and  similar traits  and  their  interaction with  similar 
environments can assist the risk assessment. 
B. In drawing conclusions for the risk  assessment referred to  in  ArtiCles  6  and  11  the following 
points should be addressed. 
1.  Identification of any hazardous characteristics of the GMO(s) 
Hazards are intrinsic characteristics of a QMO which have the potential to cause harm, either directly or 
indirectly.  Comparison  of the  identified  hazards  of the  GMO(s)  with  those  presented  by  the  non-
modified  organism  from  which  it  was  derived,  under  corresponding  conditions,  will  permit 
identification of  those hazards arising from the genetic modification.  It is important not to discount any 
hazard on the basis that it is unlikely to occur. 
2.  The extent of  the consequences of tl1e hazard being realised 
For each  hazard  identified,  the  consequences  of the  hazard  occurring  should  be  considered.  The 
evaluation of the eh.ient of  th~ consequences is affected by the environment into which the GMO(s)  is 
intended to be released and the manner of  the release. 
36 3.  The likelihood of  the hazard being re~lised 
A major factor in determining the likelihood of a hazard  being  recl.ised  is  the characteristics  of the 
environment into which the GMO(s) is ii;ltended to be released. 
4.  Estim.ation of  the risk posed by each identified hazard 
On the basis of  the hazardous characteristics, the likelihood of  them being realised and the magnitude of 
the  consequences  a  determination  of the  risk  of adverse  effects  should  be  made  for  each  hazard 
identified. 
5. Application of  management strategies for risks from the deliberate release of GMO(s) 
If  for any release the estimated risk for any identified hazardis not at an acceptable level, the GMO(s) or 
the conditions of  the release should be modified to reduce the risk. 
6.  Determination of  the overall risk of  adverse effects 
An evaluation of the overall risk of adverse effects, whether direct or indirect,  is  determined from  the 
comhined effects of  the risk from each hazard taking into account any management strategies applied. 
37 ANNEX III 
INFORMATION REQUIRED IN THE NOTIFICATION 
The notification for a deliberate release referred to in Part B or Part C of the Directive is to include  .  ' 
as appropriate, the information set out below in the sub-Annexes. 
Not all the points included will apply to every case. It is to be expected that individual notifications 
will  address  only  the  particular  subset  of considerations  which  is  'appropriate  to  individual 
situations. 
The  level  of detail  required in response to  each  subset of considerations  is  also  likely  to  vary 
according to the nature and the scale of the proposed release. 
Annex III A  applies  to  r'eleases  of all  types  of genetically  organisms  other than higher plants. 
Annex III B applies to release of genetically modified higher plants. 
The term "higher plants" means plants which belong to the taxonomic groups Gymnospermae and 
Angiospermae. 
.  38 -ANNEX IDA 
INFORMATION REQUIRED IN NOTIFICATIONS CONCERNING RELEASES OF 
GENETICALLY MODIFIED ORGANISMS OTHER THAN IUGHER PLANTS 
I.  GENERAL INFORMATION 
A. Nrutte and address of  the notifier (company or institute) 
B. Name, qualifications and experience of  the responsible scientist(s) 
· C. Title of  the project·  · · 
II. INFORMATION RELATING TO THE GMO 
A. Characteristics of (a) the donor, (b) the recipient or (c) (where appropriate) parental 
organism(s):  · 
1.  scientific name; 
2.  taxonomy; 
3.  other names (usual name, strain name, etc.); 
4.  phenotypic and genetic markers; 
5.  degree of relatedness between donor and recipient or between parental organisms; 
6.  description of identification and detection techniques; 
7.  sensitivity, reliability (in quantitative terms) and specificity of detection and dentification 
techniques; 
8.  description of  the geographic distribution and of the natural habitat of  the organism 
including information on natural predators, preys, parasites a,nd competitors, symbionts 
and hosts; 
9.  potential for genetic transfer and exchange with other organisms; 
10. verification of  the genetic stability of  the organisms and factors affecting it; 
11. pathological, ecological and physiological traits: 
(a)  classification  of hazard  according  to  existing  Community  rules  concerrung  the 
· protection of  human health and/or the environment; 
(b)  generation time in natural ecosystems, sexual and asexual reproductive cycle; 
(c)  information  on survival,  including  seasonability  and  the  ability  to  form  survival 
structures e.g.: seeds, spores or sclerotia; 
(d)  pathogenicity:  infectivity,  toxigenicity,  virulence,  allergenicity,  carrier  (vector)  of 
pathogen,  possible  vectors,  host  range  including  non-target  organism.  Possible 
activation of latent viruses (proviruses). Ability to colonize other organisms; 
(e)  antibiotic resistance,  and potential use of these  antibiotics  in humans  and  domestic 
organisms for prophylaxis and therapy; 
(f} involvement  in  environmental  processes:  primary  production,  nutrient  turnover, 
decomposition of  organic matter, respirati?n, etc. 
39 12.  Nature of  indigenous vectors: 
(a) sequence;  . 
(b) frequency of  mobilization; 
(c) specificity; 
(d) presence of  genes which confer resistance. 
13.  History of  previous genetic modifications. 
B. Characteristics of  the vector: 
1.  nature and source of  the vector; 
2.  sequence of  transposons, vectors and other non-coding genetic segments used-to construct 
the GMO and to make the introduced vector and insert function in the GMO; · 
3.  frequency of  mobilization of  inserted vector and/or genetic transfer capabilities and 
methods of  determination; 
4.  information on the degree to which the vector is limited to the DNA required to perform 
the intended function. 
C. Characteristics of  the modified organism: 
1.  Information relating to the genetic modification: 
(a) methods us-ed for the modification;-
(b) methods used_ to construct and introduce the insert(s) into the recipient or to delete a 
sequence; 
(c) description of  the insert and/or vector construction; 
(d) purity of  the insert from any unknown sequence and information on the degree to 
which the inserted sequence is limited to the DNA required to perform the intended 
function; 
(e)sequence, functional identity and location of  the altered/inserted/deleted nucleic acid 
segment(s) in question with particular reference to any known harmful sequence. 
2.  Information on the final GMO: 
(a) description ofgenetic trait(s) or phenotypic characteristics and in particular any new 
traits and characteristics which may be expressed or no longer expressed; 
(b) structure and amount of any vector and/or donor nucleic acid remaining in the final 
construction of the modified organism; 
(c) stability of  the organism in terms of  genetic traits; 
(d) rate and level of  expression of  the new genetic material. Method and sensitivity of 
measurement; 
(e) activity ofthe expressed protein(s); 
(f) description of identification and detection techniques including techniques for the 
identification and detection of the inserted sequence and vector; 
(g) sensitivity, reliability (in quantitative terms) and specificity of  dete~tion and 
identification techniques; 
(h) history of previous· releases or uses of  the GMO; 
(i) ·health considerations: 
(i)  toxic or allergenic effects of  the non-viable GMOs and/or their metabolic products; 
(ii)  product hazards; 
(iii) comparison of  the modified organism to the donor, recipient or (where 
40 appropriate) parental organism regarding pathogenicity; 
(iv) capacity fqr colonization; 
(v)  if  the organism is pathogenic to humans who are immunocompetent: 
- diseases caused and tnechanism of  pathogenicity including invasiveness and. 
virulence, 
- communicability, . 
- infective dose,  . 
- host range, possibility of  alteration, 
- possibility of  survival outside of  human host, 
-presence of  vectors or means of  dissemination, 
- biological·stability, 
- antibiotic-resistance patterns,  . 
- allergenicity,  · 
- availability of  appropriate therapies. 
III.  INFORMATION RELATING TO THE CONDITIONS OF RELEASE AND THE 
RECEIVING ENVIRONMENT 
A. Information on the release: 
1.  description of  the proposed deliberate release, including the purpose(s) and foreseen 
products; 
2.  foreseen dates of  the release and time planning of  the experiment including frequency and 
duration of releases; 
3.  preparation of  the site previous to the release; 
4.  size of  the site; 
5.  method(s) to be used for the release; 
6.  quantities of GMOs to be released; 
7.  disturbance on the site {type and method of cultivation, mining, irrigation, or other 
activities); 
8.  worker protection measures taken during the release; 
9.  ·post-release treatment of  the site; 
10. techniques foreseen for elimination or inactivation of the GMOs at the end of  the 
experiment; 
U. information on, and results of, previous releases ofthe GMOs, especially at different 
1 
scales and in different ecosystems.  · 
B. Information on the environment (both on the site and in the wider environment): 
1.  geographical location and grid reference of  the site(s) (in case of  notifications under 
Part C the site(s) of  release will be the foreseen areas of use of  the product); 
2.  physical or biological proximity to humans and other significant biota; 
3.  proximity to significant biotopes or protected areas; 
4.  size of  local population; 
5.  economic activities of  local populations which are based on the natural resources of  the 
area;  . 
6.  distance to closest areas protected for drinking water and/or environmental purpose; 
7.  climatic characteristics of  the region(s) likely to be affected; 
8.  geographical, geological and pedological characteristics; 
9.  fl~ra and fauna, including crops, livestock and migratory species; 
41 10. description of  target and non-target ecosystems likely to be affected; 
11. a comparison of  the natural habitat of  the recipient organism with the proposed site(s) of 
release;  · 
12. any known planned developments or changes in land use in the region which could 
·  influence the environmental impact of  the release. 
IV.  INFORMATION RELATING TO THE INTERACTIONS· BETWEEN THE GMOs AND 
THE ENVIRONMENT 
. A. Characteristics affecting survival, multiplication and dissemination: . 
1.  biological features which affect survival, qmltiplication and dispersal; 
2.  known or predicted environmental conditions which may affect survival, multiplicat!on 
and dissemination (wind, water, soil, temperature, pH, etc.); 
3.  sensitivity to specific agents. 
B. Interactions with the environment: 
1.  predicted habitat of the GMOs; 
2.  studies of  the behaviour and characteristics of  the GMOs and their ecological impact 
carried out in simulated natural environments, such as microcosms, growth rooms, 
greenhouses; 
3.  genetic transfer capability: 
(a) post-release transfer of  genetic material from GMOs into organisms in affected 
ecosystems; 
(b) post-release transfer of  genetic material from indigenous organisms to the GMOs; 
4.  l*elihood of post-release selection leading to the expression of  unexpected and/or 
undesirable traits in the modified organism; 
5.  measures employed to ensure and to verify genetic stability. Description of  genetic traits 
which may prevent or  minimiz~ dispersal of genetic material. 11ethods to verify genetic 
stability; 
6.  routes of biological dispersal, known or potential modes of interaction with the 
disseminating agent, including inhalation, ingestion, surface contact, burrowing, etc.; 
7.  description of ecosystems to which the GMOs could be disseminated.  · 
C.  Potential environmental impact: 
1.  potential for excessive population increase in the environment; 
2  ..  competitive advantage of  the GMOs in relation to the unmodified recipient or parental 
organism(s); 
3.  identification and description of  the target organisms; 
4.  anticipated mechanism and result of  interaction between the released GMOs and the target 
organ1sm; 
5.  identification and description ofnon-target organisms which may be affected unwittingly; 
6.  likelihood of post-release shifts in biological interactions or in host rarige; 
7.  known or predicted effects on non-target organisms in the environment, impact on · 
population levels of competitors: preys, hosts, symbionts, predators, parasites and 
pathogens;  ·  · 
8.  kno;wn or predicted involvement in  biogeo~hemical processes; 
9.  other potentially significant interactions with the environment. 
42 V. INFORMATION ON MONITORING; CONTROL, WASTE TREATMENT AND 
EMERGENCY RESPONSE PLANS 
A. Monitoring. techniques: 
1. ·methods for tracing the GMOs, and for monitoring their effects; 
2.  specificity (to identify the GMOs, and t~ distinguish them from the donor, recipient or, 
where appropriate, the parental organisms), sensitivity and reliability of  the monitoring 
techniques;  · 
3.  techniques for detecting transfer of  the donated genetic material to other organisms; -
4.  duration and frequency of  the monitoring. 
B. Control oftherelease: 
1.  methods and procedures to avoid and/or minimize the spread of  the GMO.s beyond the site 
of  release or the designated area for use; 
2.  methods and procedures to pr.otect the site from intrusion by unauthorized individuals; 
3. methods and procedures to prevent other organisms from entering the site. 
C. Waste treatment: 
1:  type of  waste generated; 
2.  expected amount of  waste; 
3.  possible risks; 
4.  description of treatment envisaged. 
D. Emergency response plans: 
1.  methods and procedures for controlling the GMOs in case of  unexpected spread; 
2.  methods for decontamination of  the areas affected, e.g. eradication of the GMOs; 
3.  methods for disposal or sanitation of plants, animals, soils, etc. that were exposed during 
or after the spread; 
4.  methods for the isolation of the area affected by the spread; 
5.  plans for protecting human health and the environment in case of  the occurrence of an 
undesirable effect. 
43 ANNEXITIB 
INFORMATION REQUIRED IN NOTIFICATIONS CONCERNING RELEASES OF 
GENETICALLY MODIFIED HIGHER PLANTS (GMPHS) 
(GYMNOSPERMAE AND ANGIOSPERMAE) 
A. GENERAL INFORMATION 
1.  Name and address of  the notifier (company or institute) 
2.  Name, qualifications and ·experienc~ of  the responsible scientist(s) 
3.  Title of  the project  .  · 
B. INFORMATION RELATING TO (A) THE RECIPIENT OR (B) (WHERE APPROPRIATE) 
PARENTAL PLANTS 
1.  Complete name: 
(a)  family name; 
(b)  genus; 
(c) 
(d) 
(e) 
spectes; 
subspecies; 
cultivar/breeding line; 
(f)  common name. 
2.  (a)  Information concerning reproduction: 
(i)  mode(s) of reproduction; 
(ii) specific factors affecting reproduction, if any; 
(iii) generation time. 
(b)  Sexual compatibility with other cultivated or wild plant species. 
3.  Survivability: 
(a)  ability to form structures for survival or dormancy; 
(b)  specific factors affecting survivability, if any. 
4. Dissemination: 
(a)  ways and extent of dissemination; 
(b)  specific factors affecting dissemination, if any. 
5.  Geographical distribution of  the plant. 
6.  Inthe case of plant species not normally grown in the Member State(s), description of  the 
natural habitat of the plant, including information on natural predators, parasites, competitors 
and symbionts. 
7.  Potentially significant interactions of  the plant with organisms other than plants in the 
ecosystem where it is usually grown, including information on toxic effects on humans, 
animals and other organisms.  · 
C. INFORMATION RELATING 1'0 THE GENETIC MODIFICATION 
1. ·Description of the methods used for the genetic modification. 
2.  Nature and source of  the vector used. 
3.  Size, source (name) of  donor organism(s)  and intended function of each constituent fragment 
of  the region intended for insertion. 
44 D. INFORMATION RELATING TO THE GENETICALLY MODIFIED PLANT 
1.  Description of  the trait(s) and characteristics which have been introduced or· modified. 
2.  Information on the sequences a~ally  inserted/deleted: 
(a) size.and structure of  the insert and methods used for its characterisation, including 
. information on any paJ:ts of  the vector mtroduced in the GMPH or any carrier or foreign 
. DNA remaining in the GMPH; 
(b) in case of deletion, size and function of  the deleted region(s); 
(c) location of  the insert in the plant cells (integrated in the chromesome, chloroplasts, 
mitochondria, or maintained in a non-intregated form), and methods for its determination; 
(d)  copy number of  the insert. 
3.  Information on the expression of  the insert: 
(a)  information on the expression of  the insert and methods u.sed for its characterization; 
(b)  parts of  the plant where the insert is expressed (e.g. roots, stem, pollen, etc.). 
4. Informationen on how the genetically modified plant differs from the recipient plant in: 
(a)  mode(s) and/or rate of  replication; 
(b)  dissemination; 
(c)  survivability. 
5.  Genetic stability of the insert. 
6.  Potential for transfer of  genetic material from the  genetically modified plants to other 
organisms.  . 
7.  Information on any toxic or harmful effects 9n human health add the environment, arising 
from the genetic modification. 
8.  Mechanism of interaction between the genetically modified plant and target organisms (if 
applicable). 
9.  Potentially significant interactions with non-target organisms. 
10. Description of detection and identification techniques for the genetically modified plant. 
11. Information about previous releases of  the genetically--modified plant, if applicable. 
E. INFCJRMATION RELATING TO THE SITE OF RELEASE (Of..TL Y FOR NOTIFICATIONS 
SUBMITTED PCRSUANT TO ARTICLES 6,  6a, 6b and 6c) 
1.  Location and size of  the release site(s). 
2.  Description of the release site ecosystem, including climate, flora and fauna. 
3.  Presence of sexually compatible wild relatives or culivated plant species. 
4.  Proximity to offtcially recognized biotopes or protected areas which may be affected. 
F.  INFORMATION RELATING TO THE RELEASE (ONLY FOR NOTIFICATIONS 
SUBMITTED PURSUANT TO ARTICLES 6,  6a, 6b and 6c) 
1.  Purpose of the release. 
2.  Foreseen date(s) and duration of the release. 
3.  Method by which the genetically modified plants will be released. 
4.  Method for preparing and managing the release site, prior to,  during and post-release, 
including cultivation practices and harvesting methods. 
5.  Approximate number of plants (or plants perm\ 
45 G.  INFORMATION  ON  CONTROL,  MONITORING,. POST-RELEASE  AND  WASTE 
TREATMENT PLANS  (ONLY FOR NOTIFICATIONS  SUBMITTED  PURSUANT TO 
. ARTICLES 6, 6a, 6b and 6c) 
1.  Any precautions taken: 
(a)..  distance(s) from sexually compatible plant species; 
(b)  any measures to miniinize/prevent pollen or seed dispersal. 
2.  Description of  methods for post~release treatment of  the site. 
3. Description of post-release treatment methods for the genetically modified plant material 
including wastes. 
4.  Description of  monitoring plans and techniques. 
5.  Description of  any emergency plans. 
. 
H.  INFORMATION ON THE POTENTIAL ENVIRONMENTAL IMPACT FROM THE 
RELEASE OF THE GENETICALLY MODIFIED PLANTS 
1.  Likelihood of  the GMPH becoming more persistent than the recipient or parental plants in 
agi:icultural habitats or more invasive in natural habitats. · 
2. · Any selective advantage or disadvantage conferred to other sexually compatible plants 
species, 
which may result from genetic transfer from the genetically modified plant. 
3.  Potential environmental impact of  the interaction between the genetically modified plant and 
target organisms (ifapplicable).  , 
4.  Possible environmental impact resulting from potential interactions with non-target 
organisms. 
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ADDITIONAL INFORMATION REQUIRED IN THE CASE OF NOTIFICATION FOR PLACING 
ON THE MARKET 
A  The following information shall be provided in the notification for placing on the market of 
products, in addition to that of  Annex III: 
1.  name of  the product and names of  GMOs contained therein; 
2.  name of  the manufacturer or distributor and his address in the Community; 
3.  specificity of  the product, exact conditions of use including, when. appropriate, the type 
of  environment and/or the geographical area(s) of  the Community for which the product 
is suited; 
4.  .  type of expected use: industry, agriculture and skilled trades, consumer use by public at 
large.  _ 
5.  infon:n,ation relating to the introduced genetic modification which could be of relevance 
to the establishment of a possible register of modifications  introduced in organisms 
(species). This may inch~de nucleotide sequences or other type of information·which is 
relevant to the inclusion in such a register. 
B.  The following information shall be provided, when relevant,  in addition to that of point A,  in 
accordance with Article 11 of  this Directive: 
1.  measures to take in case of  unintended release or misuse; 
2.  specific instructions or recommendations for storage and handling; 
3.  estimated production in and/or imports to the Community; 
4.  proposed packaging.  This must be appropriate so  as to avoid unintended release of the 
GMOs during storage, or at a later stage; 
5.  proposed  labelling.  This must include,  at least in  summarized  form,  the information 
referred to in points A.  1, A. 2, A.3, B.  1 and B. 2 
C.  The  following  infom1ation  concerning  labelling  shall  be  provided  m  the  notification,  m 
accordance with Article 11 of  this Directive: 
1.  A Proposal for a mandatory labelling "this product contains GMOs", either on a label or 
in accompanying document, whenever there is evidence of  the presence of GMOs in the 
product. 
2.  A  Proposal  for  a  mandatory  labelling  "this  product 'may contain  GMOs"  where the 
presence of GMOs  in a  product cannot be excluded  but there  is  no  evidence of any 
presence of GMOs. 
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CRITERIA FOR CLASSIFICATION OF RELEASES PROVIDED FOR IN ARTICLE 6 
A.  Part B releases shall be classified into category I if  they satisfy the criteria set out below 
I. The taxonomic status and the biology (e.g. mode of  reproduction and pollination, ability to 
cross  with  related  species)  of the  non-modified  (recipient)  organism  should  be  well-
known; 
2.  There  should  be  sufficient  knowledge  about  the  safety  for  human  health  and  the 
environment of  the non-modified (recipient) organism in the environment of the release; 
3. The genetically  modified  organism  should  not present  additional  or increased  risks  to 
human health and/or the environment under the conditions of  the experimental release that 
are not presented by releases  of the  corresponding non-modified  organism  in terms  of 
pathogenicity, allergenicity, toxigenicity.  The capacity to spread in the environment and 
invade  other  unrelated  ecosystems  and  capacity  to  transfer  genetic  material  to  other 
organisms in the environment should not create any adverse effect. 
B.  Part B releases shall also be classified into Category I if the release is similar, in terms of the 
genetically  modified  organism(s)  involved  and  the  conditions  applied,  to  other  releases 
which have already been given consent to and where the results submitted in accordance with 
Article 8 have not sho\vn risks to hu;.11an health and/or the environment. 
48 ANNEX VI. 
GUIDELINES-FOR THE ASSESS.MENT REPORTS 
FORESEEN BY ARTICLE 12 
The assessment report foreseen by Article 12 should include in particular the following : 
1.  Identification  of the  characteristics  of the  rec1p1ent  organism  which  are  revelant  to  the 
assessment of the  GMO(s)  in question.  Identification of any  known risks  to  human health 
and/or the environment resulting from the release into  the  environment of the recipient non-
modified organism; 
2..  Assessment of whether the genetic modification has  been  characterised sufficiently for  the 
purpose of  evaluating any risks to human health and/or the environment; 
3.  Detailed description of  the result of the genetic modification in the modified organism; 
4.  Identification of any new risks to human health and/or the environment that may arise from the 
release  of the  GMO(s)  in  question  as  compare-d  to  the  release  of the  corresponding  non-
modified organism(s) based on the risk assessment as described in Annex II; 
5.  A conclusion on  whether the GMO(s) in question should be placed on the market in or as  (a) 
product(s)  and  under which  conditions  or whether  an  additional  assessment is  required on 
certain aspects. The aspects which require additional assessment should be specified. 
49 ANNEX VII 
The monitoring plan foreseen by Article 11(2) shall provide for the appropriate methods and 
measures  to  identify  any  relevant girect,  indirect,  immediate or delayed  effects  on human 
health and/or the environment taking into  account in  particular the following  elements  if 
.  ' 
appropriate: 
•  human health considerations 
potential of  the GMOs for pathogenic, toxic or allergenic effects 
capacity of  the GMOs for colonization 
- potential  of the  GMOs  to  compromise  the  efficacy  of therapeutic,' prophylactic  or 
diagnostic measur~s 
•  environmental considerations 
- potential of  the GMOs to persist and spread in the environment 
- potential of  the GMOs for interactions with target or non-target organisms 
- potential of the GMOs to affect population dynamics 
o  effects resulting from potential horizontal gene transfer 
•  phenotypic and genetic stability of  the GMOs 
50 CONSOLIDATED TEXT 
PART A 
General provisions 
Article 1 
1.  The  objective  of this  Directive  is  to  approximate  the  laws,  regulations- and  administrative 
provisions  of the  Member_ States  and  to  protect  human  health  and  the. environment when 
·  carrying out the deliberate release of  genetically modified organisms into the environment 
_a)  for research and development purposes or for any other purposes other than placing 
on the market 
b) for placing on the market of  genetically modified organisms as or in products. 
2.  This Directive shall not apply to the carriage of genetically modified organisms by rail,  road, 
inland waterway, sea or air. 
Article·2  · 
Forthe purposes of  this Directive: 
1.  'organism' is any biological entity capable of  replication or of transferring genetic material; 
2.  'genetically modified organism (GMO)' means  an organism in which the genetic material has 
been altered in a \vay that does not occur naturally by mating and/or natural recombination. 
Within the terms of this definition: 
a)  genetic modification occurs at least through the use of the techniques listed in Annex I A 
Part 1; 
b)  the techniques listed in Annex I_A Part 2 are not considered to result in genetic 
modification; 
3.  'deliberate release'  means  any  intentional introduction  into  the  environment of a  GMO  or  a 
combination  of G110s  without  provisions  for  containment  such  as  physical  barriers,  or  a 
combination of physical barriers together with chemical and/or biological barriers used to  limit 
their contact with the general population and the environment; 
4.  'placing on the market' means supplying or making available to third parties. 
5.  'notification' means  the presentation of documents  containing the requisite information to  the 
competent authority of a Member State. The person making the presentation shall be referred to 
as  'the notifier'; 
51 6.  'environmental risk assessment' means the evaluation of the direct and indirect risks to human 
health and the environmentwhich the deliberate release of GMOs  into the environment may 
pose.· 
Article 3 
This Directive shall not apply  to organisms obtained through the techniques of genetic modification 
· listed in Annex I B. 
Article 4 
l. Member States shall ensure that all appropriate measures are taken to avoid adverse effects on 
human health.and the environment which might arise from the deliberate release of GMOs. To 
this end GMOs may only be deliberately released into the environment following an assessment 
of any potential risks for human health and/or the environment in conformity with part B or part 
C of this Directive. The risk assessment shall take account of the principles laid down in Annex 
.  . 
II. 
2  .. Member States shall designate the competent authority or authorities responsible for carrying out 
the requirements of  this Directive and its Annexes. 
3. Member States shall ensure that the competent authority organizes inspections and other control 
measures as appropriate, to ensure compliance with this Directive. 
PARTB 
Deliberate release of Gi-.:10s  into the environment for research and development purposes or for any 
other purpose than for placing on the market 
Article 5 
Articles  6  to  9  shall  not  apply  to  any  products  under  development  covered  by  Community 
legislation which provides for a specific environmental risk assessment similar to that laid down in 
those articles. 
Article 6 
l. Any person, before submitting a notification under Articles 6a, 6b and 6c concerning the release 
of a GMO or of a combination of GMOs for the purpose of research and development, or for any 
other purpose than for placing on the market, shall carry out a risk assessment of the deliberate 
release of GMOs as  regards the risks to human health and/or the environment that may occur, 
taking due account of  the information which may be necessary for evaluating any potential risks, 
whether immediate or delayed,  which the release  may  present for  human health and/or  the 
environment. This information is laid down in Annex III.  . 
52 2.  Deliberate releases which fall under this part are classified in 2 categories: 
Category  I:  Deliberate releases of  GMOs which comply with the criteria set out in Annex V 
· parts A orB 
Cat~gory II: All other releases. 
Article 6a 
L  Any person before undertaking a Category I deliberate release of a GMO or of a combination of 
GMOs,  shall submit a  notification to  the competent authority referred to in Article 4(2) of the 
Member State within whose territory the release is to take place. 
2. The notification referred to in paragraph 1 shall include: 
a technical  dossier supplying the information on the basis  of which  the  classification of the 
.  deliberate release was made. The notification referred to in paragraph 1 shall include a technical 
dossier  supplying  .the  information  specified  in  Annex  III  necessary  for  evaluating  any 
foreseeable risks from the deliberate release of a GMO or combination of GMOs, in particular: 
a)  information relating to the GMO(s), 
b)  information relating to the conditions of  release and the receiving environment, 
c)  information on the interactions between the GMO(s) and the environment, 
. d)  a statement evaluating the impacts and risks posed by the GMO(s) to human health or 
the environment from the uses envisaged; 
3.  The competent authority shall verify the classification into  Category I in accordance with the 
criteria referred to in Article 6(2) and shall examine the dossier for any potential risks to human 
health and/or the environment.  The competent authority shall respond in writing to  the notifier 
\Vi thin 30 days of receipt of  the notification by either: 
a)  indicating that it is satisfied that the notification is in compliance with this Directive and that 
the release may proceed, or  · 
b)  indicating that the release does not fulfil the conditions of this Directive and the notification 
is therefore rejected. 
4.  Before this  Directive is  implemented,  the Commission shall  establish in accordance \Vith  the 
procedure laid dmvn in Article 21  the minimum amount.oftechnical information from Annex III 
to be included in the dossier referred to in paragraph 2. 
Article 6b 
1.  Any person before undertaking a Category II deliberate release of a GMO or of a combination of 
GMOs;  must submit a notification to the competent authority referred to in Article 4(2) of the 
Member State within whose 'territory the release is to take place.  · 
53 2.  The notification referred  to  in paragraph I  shall  include  a  techrucal  dossier  supplying  the 
information specified  iii Annex  III  necessary  for  evaluating  any  foreseeable  risks  from  the 
deliberate release of a GMO or combination of GMOs, in particular: 
a)  general information including information on personnel and training, 
b) information relating to the GMO(s), 
c)  information relating to the conditions of  release and the receiving environment, 
d) information on the interactions between the GMO(s) and the environment, 
e)  information on monitoring, eontrol, waste treatment and emergency response plans; 
f)  a statement evaluating the impacts and risks posed by the  GMO(s)  to  human health .or the 
environment from the uses envisaged; 
3.  The  competent  authority,  having  considered,  where  appropriate,  any  observations  by  other 
Member States made in accordance with Article 9, shall respond in writing to the notifier within 
90 days of  receipt of  the notification by either: 
a)  indicating that it is satisfied that the notification is in compliance with this Directive and that -
the release may proceed, or  · 
b) indicating that the release does not fulfil the conditions of this Directive and the notification 
is therefore rejected. 
4.  For the purpose of  calcul~ting the 90-day period referred to in paragraph 3, any periods of time 
during which the competent authority: 
a)  is awaiting further information which it may have requested from the notifier, 
or 
b)  is carrying out a public inquiry or consultation i.n accordance with Article 7 
shall not be taken into account. 
5.  The notifler may  proceed with the release only when he has received the written consent of the 
competent authority, and in conformity with any conditions required in this consent 
Article 6c 
1.  In the case of part B releases planned to  take place  in  more than one Member State,  the 
applicant may choose to follow the procedure outlined in the following paragraphs. 
2.  A notification shall be submitted to the Commission and to the .competent authorities of the 
Member  States  where the  release  is  to  be  carried  out.  The  notification  shall  include  a 
technical dossier supplying the information outlined in Article 6a(2) for deliberate releases 
under category  I  or Article  6b(2)  for  all  other releases  together with  a  summary  of the 
technical dossier. 
3.  Upon receipt of the notification the Commission shall forward the summary of the dossier 
to  the  competent  authorities  of those  Member  States  which  have  not received  the  full 
dossier. The competent authorities may forward comments within 60 days of receipt of the 
notification to the Commission. The Commission may immediately forward these comments 
to the competent authorities referred to in par'agraph 2. 
54 ---~-----------------------
4.  The notifier shall submit any additional information which may have been requested by one 
of  the competent authoriti~ referred to in paragraph 2 to the Commission and all the other 
competent authorities referred.to in paragraph 2. 
.  . 
· 5.  The competent authorities referred to in paragraph 2,  having considered any comments by 
other competent authorities, shall respond in writing to the notifier within 90 days of  receipt . 
of  the notification by either:  -
a)  indicating that it is satisfied that the notification is in compliance with this Directive and 
that the release may proceed on their territory or 
b)  indicating that the release does not fulfil the conditions of this Directive and the release 
cannot take place on their territory. 
6.  For the purpose of  ~alculating the 90-day period referred to in paragraph 5,  any periods of 
time during which the competent authorities 
a)  are awaiting further information which it may have requested from the notifier, 
or 
b)  · are carrying out a public inquiry or consultation in accordance with Article 7 
shall not be taken into account.· 
Article6d 
1.  In  the  event of any  modification of the  deliberate  release  of GMOs  or of a  combination of 
GMOs which could have consequences with regard to  potential risks for human health or the 
environment  or  if new  information  has  become  available  on  such  risks,  either  while  the 
notification  is  being  examined  by  the  competent  authority  of a  Member  State  or  after  that 
authority has given its written consent, the notifier shall immediately: 
a)  revise the measures specified iii the notification, 
b)  revise the measures specified in the notification, inform the competent authority in advance of 
any modification or as soon as the new information is available, 
c)  take the measures necessary to protect human health and the environment 
2.  If information becomes  available  subsequently to  the  competent  authority ·which  could  have 
significant consequences for the risks posed by the release, the tompetent authority may require 
the notifier to modify the conditions of, suspend or terminate the deliberate release. 
Article 7 
Where a Member State considers it appropriate, it may provide that groups cir  the public shall be 
consulted on any aspect of  the proposed deliberate release. 
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After completion of a release, the notifier shall send to the competent authority the result of the 
release in respect of any risk to huma.Ii health or the environment, with particular reference to any 
kind of  product that the notifier intends to notify at a later stage.  · 
Article 9 
1.  The  competent authorities  shall  send  to  the  Commission,  within  30  days  of its  receipt, ·a 
summary of each Category II  notification received under Article 6b. The format of  this summary 
will be established by the Commis~ion  in accordance with the procedure laid down in Article 21. 
2.  The Commission shall immediately forward these summaries to the other Member States, which 
may, within 30 days, present observations through the Commission or directly. 
3.  The competent  ~uthorities shall·mform the other Member States  and the Commission of the 
final decisions taken in compliance with Article 6b(3) and 6c(5) and of  the results of  the releases 
received in accordance with Article 8. 
4.  Once a year Member States shall send to the Commission and the competent authorities of the 
other Member States a  lis~ of GMOs which have been released on their territory in accordance 
with Article 6a(3)(a) and a  list of notifications  that were ·rejected  in accordance with Article 
6a(3)(b). 
PARTC 
Placing on the market of products containing GMOs 
Article 10 
1.  Articles 11  to  18  shall  not apply  to  any  products  covered  by  Community  legislation which 
provides for a specific environmental risk assessment similar to that laid down in this Directive. 
Article 11 
1.  Before a  GMO or a  combination of GMOs  are  placed on the  market as  or in  a  product,  a 
notification shall be submitted to  the competent authority of the Member State where such a 
product is  to be placed on the market for the first time.  Upon receipt of the notification the 
competent authority shall without delay forward a  copy of the notification to the Commission 
and to the competent authorities of the other Member States. 
2.  The notification shall contain: 
a)  the information required in Annexes III and IV. This information shall take into account the 
diversity of sites of use of the product and  shall include  information on data and  results 
56 obtained from research and. developmental releases concerning the impact of the release on 
human health and(  or the environment; 
b) an assessment of any risks for human health and/or the environment related to the GMOs or 
the combination of GMOs contained in the product, taking due aceount of the principles laid 
do:Wn in Anne~  II;  · 
c)  the conditions for the placing on the market of the product, including specific conditions of 
use and. handling; 
d)  a detailed plan for monitoring in order to identify any relevant direct, indirect, immediate or 
delayed effects of  the GMOs on human health and/or the environment in accordance with the 
requirements outlined in  Annex VTI; 
e) .a proposal forlabelling which shall comply with the requirements laid down in Annex IV and 
which shall inform the consumer of  the presence of GMOs in the product(s) whenever there is 
evidence that the product(s) contain(s) GMOs. 
f)  a proposal for packaging which shall comprise the requirements laid down in Annex IV. 
If on the  basis  of the results  of any  ~elease notified  under  Part B  of this  Directive,  or on 
substantive, reasoned scientific grounds, a notifier considers that the. placing -on the market and 
use of a· product do not pose a risk to human health and the environment, he may propose not to 
comply with one or more of  the requirements of Annex IVB. 
3.  The notification shall also include a summary of the dossier. The format of the summary shall be 
established in accordance with the procedure laid down in Article 21. 
4.  The notifier shall include in this notification information on data or results from releases of the 
- -
same GMOs or the same combination of GMOs  previously or currently notified and/or carried 
out by the notifier either inside· or outside the Community. 
5.  The notifier may also refer to  data or_results  from notifications previously submitted by other 
notifiers, provided that the latter have given their agreement in writing. 
6.  In order for a G:NIO  or combination of GMOs  to be used for  a use different than that already 
specified in a notification, a separate notification shall be submitted. 
Article 12 
1.  On receipt and after acknowledgement of  the notification referred to in Article 11, the competent 
authority shall examine it for compliance with this Directive. 
2.  At the latest 90 days after receipt of the notification, the competent authority shall forward to the 
Commission its assessment report. 
3.  The assessment report shall indicate whether the GMO(s)  in question should be placed· on the 
market and under which conditions, if  any, or whether additional assessment is required. 
57 The assessment reports  shall  be  established  in accordance. ~ith the  guidelines  laid  down  in 
Annex VI. 
4.  For the purpose of calculating the 90-day period referred to in paragraph 2, any periods of time 
during. which  the  competent  authority  is  awaiting  further  information  which  it may  liave 
reque~ted from  the ·  notifier  shall  n~t be taken  into  account.  The  competent  authority  shall 
motivate  any  request for further  information.  It shall inform  the  Commission and  the  other 
competent authorities of  any additional information submitted by the notifier. 
· Article 13 
1.  On  receipt  of the  assessment  report  referred  to  in  Article 12(2),  the  Commission  shall 
immediately forward it  to the competent authorities of  all Member States. 
2.  In the case of a favourable assessment by the competent authority referred to in paragraph 1,  a 
competent authority designated under Article 4(2)  or the Commission may make comments or 
present reasoned objections to  the placing on the market of the  GMO(s)  in question within a 
period of  30 days from the date of  circulation of  the assessment report by the Commission. 
Comments or objections of competent authorities and replies by the notifier shall be forwarded 
to the Commission which shall immediately circulate them to all competent authorities. 
The Competent Authorities  and the Commission may discuss  any  outstanding issues with the 
aim of arriving at an agreement within 60  days  from the date of circulation of the assessment 
report. 
3.  In the absence of any reasoned objection from another Member State or the Commission within 
30  days  following the date of distribution of the  assessment report or if possible outstanding 
issues are resolved '.vithin the 60 day period referred to  in paragraph 2,  the competent authority 
that hadoriginally received and  assessed the dossier shall give its consent in '.vriting 'vithin 30 
days  so that the product can be placed on the market and shall inform the other Member States 
and the Commission thereof. 
Article 13a 
1.  By way of derogation from the procedures outlined in Articles  11,  12,  13  and 13c, the procedure 
laid. down  in  Article  13b  shall  apply  to  GMOs  which  meet  the  criteria  and  information 
requirements established according to the following procedure. 
2.  The Commission, on its own initiative or on the proposal of a competent authority, may  adopt 
criteria and  information requirements  to  be met for  the  notification of deliberate releases  for 
placing on the market of certain types of GMOs as or in products under the simplified procedure 
laid  down  in  Article  13b,  after  consultation  of the  relevant  Scientific  Committee(s),  in 
accordance  with  the  procedure  laid  down  in  Article  21.  The  criteria  and  the  information 
requirements  shall  be based  on safety  to  human  health  and/or  the  environment  and  on  the 
scientific evidence available on such safety and  on the  experience  gained with the release of 
comparable GMOs. 
58 3.  Before the decision  procedure in accordance with Article  21  on a  decision  for  criteria and 
information requirements referred to  in paragraph 2  is  initiated,  the  Commission shall make 
available to the public this proposal: The public may make comments within 60 days. 
Article 13b 
1.  For GMOs for which the criteria and information requirements have been laid down according 
to ArtiCle 13a(2), the notifier shall submit a notification including a summary of the dossier to 
the competent authority of the.Member States where the product is to be placed on the market 
for the first time. 
2.  The competent authority shall respond in writing to the notifier within 15  days of-receipt of the 
notification by either: 
a)  indicating  that  the  notification  is  in  compliance  with  the  cntlena  and  information 
requirements established according to Article 13a and that the notification is accepted to be dealt 
with under the simplified procedure or 
b) indicating  that  the  notification  does  not  fulfil  the  conditions  for  the  application  of the 
simplified procedure and that the notification is rejected. 
3.  In  the  case  where  the  notification  is  rejected  the  competent  authority  shall  inform  the 
Commission and the competent authorities of  the other Member States thereof. 
4.  In cases where the notification is  accepted to  be dealt with under the simplified procedure, the 
competent authority shall circulate the notification dossier to the Commission and the competent 
authorities of the other Member States without delay.  Upon receipt the Commission shall make 
available to the public the summary of  the notification dossier. 
5.  The  competent  authorities  or  the  Commission  may  make  comments  or  present  reasoned 
objections to  the  placing on the market of the GMO(s) .in  question within a period of 30  days 
from the date of circulation of the notification dossier. The comments or objections and  replies 
by the notifier shall be forwarded to the Commission which shall immediately Circulate them to 
all  competent  authorities.  The Competent Authorities  and  the  Commission  may  discuss  any 
outstanding issues  with the aim of arriving at  an  agreement within 45  days  from  the  date  of 
circulation of the notification. 
6.  In the absence of any reasoned objection from a competent authority of a Member State or the 
Commission within 30 days  following the date of circulation of the notification dossier  or  if 
possible outstanding issues are resolved within the,  45  day period referred to in paragraph 5,  the 
competent authority that received the original notification shall give its consent in writing within· 
15  days so that the product can be placed .on the market and shall inform the Commission and 
the competent authorities of  the other Member States thereof. The consent shall be granted for a 
fixed period of seven years.  · 
59 Article 13c 
1.  By way of derogation from the procedure outlined in Article 11,  12,  13  and 13b the following 
procedure shall apply to the renewal of  the consent. 
2.  The notifier shal_l submit at the latest )2 months before the end of the eonsent a notification to 
the Commission which shall contain in particular 
a)  a copy of  the consent to the placing on the market of the GMOs, 
b) a report on the results of  the monitoring which was carried out according to Article 13e(2) 
and  · 
c)  any other new information whichhas become available with regard to· the risks of the product 
to human health and/or the environment. 
3.  On receipt of the notification referred to  in paragraph 2,  the  Commission  shall immediately 
forward it  to the Competent Authorities of all Member States. 
Comments  or reasoned  objections .  to  the  renewal  of the  consent  shall  be forwarded  to  the 
Commission within 30 days from the date of submission of the notification.  The Commission 
shall without delay circulate any comments or objections to all competent authorities. 
The  competent  authorities  of the  Member  States  and  the  Commission  may  discuss  any 
outstanding  issues  with the  aim  of arriving  at  an  agreement  within  45  days  following  the 
circulation of  the notification. 
4.  In the absence of any reasoned objection from  a Member State or the Commission within 30 
days  following the date  ~f submission referred to  in paragraph 3, the competent authority that 
received the original notification shall give its consent in writing for the renewal of the original 
consent and  shall inform the other Member States  and  the  Commission thereof.  The consent 
shall be granted for a fixed period of seven years .. 
5.  Following a notification for the renewal of a consent in accordance with paragraph 2,  the notifier 
may continue to  place the GMOs on the market under the conditions specified in that consent 
until a final decision has been taken on the renewal of  the consent. 
Article 13d 
L In cases where an objection is raised an9 maintained in accordance with Article 13(2), 13b(5) or 
13c(3), or an additional assessment is required in accordance with Article 12(3), the Commission 
shall  take  a  decision  within  three  months  in  accordance  with  the  procedure  laid  down  in 
Article 21. 
For the purpose of calculating the three month period,  any  period  of time during which  the 
Commission is awaiting further information which it may have requested from the notifier or is 
seeking the opinion of a Scientific Committee which ha.S been consulted shall not be taken into 
account. 
2.  Where the Commission has taken a favourable decision, the competent authority that received 
the original notification shall,give, within 30 days following the publication of the Commission 
60 decision, consent in writing to the notification so·that the product.may be placed on the market 
for the period of seven years and shall inform the other Member States and  the Commission 
~~  I 
Article 13e 
•  I 
I.  Once· a product has  received  a written  consent,  it may be  used  ':Vithout  further  notification 
throughout the  Community in so far as  the specific conditions  of use  and  the envifont;llents 
and/or geographical areas stipulated in these conditions ate strictly adhered to. 
2.  Following the placing on the market o( (a) GMO(s) as or in a product, notifier(s) shall carry out 
mpnitoring according to the plan referred to in Article 11(2) and the conditions specified in the 
consent.  Regular  reports  of this  monitoring  shall  be submitted  to  the  Commission  and  the 
competent authorities of  Member States. 
3.  Consent to  the placing on the market of GMOs  in or as  a product shall be granted for a  fixed 
period of  seven years.  The notifier may proceed with the placing on the market only when he 
has received the written consent of the compet~nt authority in accordance with Articles 13,  13b, 
13c  and 13d,  and  in  conformity  with  any  conditions,  including  reference  to  particular 
ecosystems/environments, required in that consent. 
·  4.  If  new information has become available with regard to the risks of the product to human health 
or the environment, either before or after the written consent, the notifier shall immediately: 
a)  revise the information and conditions specified in the notification dossier, 
b)  inform the competent authority, and 
c)  take the measures necessary to protect human health and the environment 
5.  If the  competent  authority  receives ·additional  information  pursuant  to  paragraph  4,  it shall 
immediately inform the Commission and the competent authorities of the other Member States. 
6.  Member States shall take all necessary measures to ·ensure that users comply with the conditions 
ofuse specifiedin thewritten consent. 
Article 14 
Member  States  shall  take  all  necessary  measures  to  ensure that  the  labelling  and  packaging of 
products containing, or consisting of, GMOs comply with relevant proposal in the dossier and with 
the relevant requirements  specified  in  the  written  consent referred  to  in  Articles 13(3), ·13b(6), 
13c(4) or 13d(2). 
Article 15 
Member States may not,  on grounds relating to the notification and written consent of the placing 
on the  market  under  this  Directive,  prohibit,  restrict  or impede  the  placing  on the  market of 
products containing, or consisting of, GMOs which comply with the requirements of  this Directive. 
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1.  Where a Member State, as a result of new information or reassessment of existing information, 
has  detailed grounds for considering that a product which has  been properly notified and has 
received  written  cons~nt  · under  this  Directive  constitutes  a  risk  to  human  health  or  the 
envir<;mment,that Member State  may provisionally restrict or prohibit the use and/or sale of that 
product on its  territory.  It shall immediately  inform the  Commission  and  the other Member 
States of such action and give reasons for. its decision. 
2.  A decision shall be taken on the matter within three months  in accordance with the procedure . 
laid down in Article 21.  · 
Article 17 
1.  Without prejudice to Article 19, upon receipt of a notification in accordance with Article 11(1) 
the Commission shall immediately make  available  to  the  public  the  summary  referred to  in 
Article  11(3).  The  public  may  make  comments  within  30  days.  The  Commission  shall 
immediately forward the comments to all competent authorities ofthe Member States. 
2.  Without prejudice to Article 19,  all GMOs which have received written consent for the placing 
on  the  market or  whose .placing  on  the  market  was  rejected  as  or  in  products  under  this 
Directive, the assessment reports carried out for these GMOs and the opinion(s) of the Scientific 
Committees  consulted shall be made  available to  the  public.  For each  product,  the  GMO  or 
GMOs contained therein and the use or uses shall be clearly specified. 
3.  Without prejudice to Article 19, upon receipt the Commission shall make available to  the public 
the information referred to in Article 9(3) and (4). 
Anicle 18 
1.  Member States shall send to  the Commission, at the end of each year,  a brief factual report on 
the their experience with the GMOs placed on the market in or as products u~der this Directive. 
2.  The Commission shall send to  the European Parliament and  the Council,  every three years,  a 
report  on  the  experience  of Member  States  with  GMOs  placed  on  the  market  under  this 
Directive, 
3.  \Vhen submitting this report for the fust time,  the Commission shall at the same time submit a 
specific report on the operation of this Part of this Directive including an assessment of all  its 
implications. 
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Fihal provisions 
Article 19 
1.  The Commission and the competent authorities shall not divulge to third parties any confidential 
information notified or exchanged under this  Directive and  shall protect intellectual property 
rights relating to the data received.  · 
2.  The notifier may indicate the information in the notification submitted under this Directive, the 
disclosure of which might harm  his  competitive position,  thaf should therefore -be  treated  as · 
confidential. Verifiable justification must be given .in such cases. 
3.  The Competent Authority shall decide, after consultation with the notifier, which information 
will be kept confidential and shall inform the notifi-er of  its decisions. 
4. In no case may the following information when submitted according to Articles 6a,  6b,  6c,  6d, 
11,  13b or 13c be kept confidential: · 
description of  the GMO or GMOs, name and address of the notifier, purpo-se of the release 
and location of  release; 
rnethods and plans for monitoring of  the GMO or GMOs and for emergency response; 
the evaluation  of foreseeable  effects,  in  particular  any  pathogenic  and/or  ecologically 
disruptive effects. 
5.  If,  for whatever reasons, the notifier withdraws the notification,  the  competent authorities and 
the Commission must respect the confidentiality of the information supplied. 
Article 20 
According to the procedure laid down in Article 21, the Coml}lission shall adapt Aiinexes II to VII 
to technical progress. 
Article 20a 
The relevant  Scientific Committee(s) shall be consulted by the Commission on any matter which is 
likely to have an  effect on human health and/or the environment before the decision procedure 
n~ferred to in  Articles 13d(1) or 16(2) is initiated.  · 
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Where the procedure defined in this Article is to be implemented, the Commis~ion  shall be assisted 
by a  committee  composed  of the  representatives  of the  Member  States  and  chaired  by the 
representative of  the Commission, hereinafter referred to as the 'Committee'. 
The representative of the Commission shall submit to the rommittee a draft of the .measures to be 
taken. The Committee shall deliver its opinion on the draft within a time limit which the Chairman 
m~y lay  down according to the urgency of the matter.  The opinion shall be delivered by the 
majority laid down in Article 148 (2) of the Treaty in the case of decisions which the Council ·is 
required to  adopt on a  proposal from the Commission.  The votes of the representatives of the 
Member States within the committee shall be weighted in the manner set out ln. that Article. The 
Chairman shall not vote. 
The .Commission shall adopt the measur~s envisaged if  they are in accordance with the opinion of 
the Committee: 
If  the measures· envisaged are not in accordance with the opinion of  the Cpmmittee, or if no opinion 
is delivered, the Commission shall, without delay, submit to the Council a proposal relating to the 
measures to be taken. The Council shall act by a qualified majority. 
If, on the expiry of a period of three months from the date of referral to the Council, the Council 
has not acted, the proposed measures shall 'be adopted by the Commission, save where the Council 
has decided against the said measures by a simple majority. 
Article 22 
1.  Member  States  and  the  Commission shall  meet .regularly  and  exchange  information  on the 
experience acquired with regard to the prevention of risks related to  the release of GMOs into 
the environment. 
2.  Every three years, Member States shall send the Commission a report on the measures taken to 
implement the provisions of  this Directive, the first time being on 1 September  19~2. 
3.  Every three years, the Commission shall publish a summary based on the reports referred to  in 
paragraph 2,  the first time being in 1993. 
Article 22ii 
Member States shall determine the sanction· arrangements applicable to  violations of the national 
provisions  made  pursuant  to  this  Direct~ve,  and  take  any  measure  necessary  to· ensure  their 
implementation.  The  sanctions  thus  envisaged  must  be  effective,  proportional  and  dissuasive. 
Member States  must notify these provisions to  the  Commission  at the latest by  ......... [the  date 
mentioned in Article 2of  the amending Directive], and any later: modification concerning them as 
soon as possible. 
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.  I  :  .. 
. Before .......... [a date seven years after the date forseen for the transposition according to Article 2 
of the amending Directive], the consents granted for pl~cing on the market of products containing 
or consisting of GMOs before ........... [the date mentioned in Article 2·of the amending Directive] 
shall be renewed according to the procedure outlined in Article 13c. 
Article 23 
1.  Member  States  shall  bring  into  force  the  laws,  regulations  and  administrative  provisions 
necessary to comply with this Directive not later than 23 October 1991. 
2.  Member  States  shall  i.mplediately  inform  the  Commission  of  all  laws~  regulations  and 
administrative provisions adopted in implementation of  this Directive. 
Article 24 
This Directive is addressed to the Member States: 
65 ANNEX/A 
TEGHNIQUES REFERRED TO IN ARTICLE 2 (2) 
PART 1 
Techniques ofgenetic modification referred to in Article 2 (2) (a) are inter alia: 
(1)  recombinant nucleic acid  te~hniques involving the formation of new combinations of genetic 
material by the insertion of nucleic acid molecules produced by whatever means outside an 
organism, into any virUs, bacterial plasmid or other vector system and their incorporation into a 
host organism in which they do not naturally occur but in which they are capable of continued 
propagation; 
(2)  techniques involving the direct introduction into  an organism of heritable material prepared 
outside the organism including micro-injection, macro-injection and micro-encapsulation; 
(3)  cell fusion (including protoplast fusion) or hybridisation techniques where live cells with new 
combination~ of heritable genetic material are formed through the fusion of tWo or more cells 
by means of methods that do not occur naturally. 
PART2 
Techniques  referred  to  in  Article 2 (2) (b)  which  are  not  considered  to  result  in  genetic 
modification, on condition that they do  not involve the use of recombinant nucleic acid molecules 
or genetically  modified  organisms  made  by  techniques/methods  other  than  those  excluded  by 
Annex IB: 
(1)  in vitro fertilization; 
(2)  natural processes such as:  conjugation, transduction, transformation, 
(3)  polyploidy induction.  , 
66 ANNEXIB 
TECHNIQUES REFERRED TO IN ARTICLE 3 
.  . 
·Techniques/methods of  genetic modifica:tiOJ?. yielding organisms to be excluded from the Directive, 
on the  condition  that  they  do  not involve  the  use  of recombinant  nucleic  acid  m-olecules  or 
genetically  modified  organisms  other  than  those  produced  by  one  or  more  of  the 
techniques/methods listed below are: 
(1)  mutagenesis, 
(2)  cell fusion (including protoplast fusion) of  plant cells where the resulting organisms can also be 
produced by traditional breeding methods. 
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ANNEX II 
Principles for the environmental risk assessment 
A. The environmental ;isk ~sessment  referred to in Articles 6 and II. shall take into account the 
following: 
I. Elements which may be considered as potentially harmful effects 
pathogenicity to humans, animals or plants 
_compromising of  prophylactic or therapeutic treatments 
effects on population dynamics within the receiving environment 
effects on geochemistry 
the uncontrolled spread of  the GMO(s) in the environment and invasion of  unrelated 
ecosystems 
effects resulting from the transfer of  the inserted genetic material to other organisms 
.  phenotypic and genetic instability 
2.  Elements which form the basis of  the risk assessment: 
the characteristics of  the non-modified organism(s) and of the 
introduced trait(s) which give· rise to the GMO(s); 
the characteristics of  the intended use; 
the receiving environment, and 
the interaction between these 
Information from  releases  of similar organisms  and  similar  traits  and  their interaction with  similar 
environments can assist the risk assessment. 
B. In drawing conclusions  for the risk assessment referred to  in  Articles  6 and  11  the following 
points should be addressed. 
1.  Identification of any hazardous characteristics of the GMO(s) 
Hazards are intrinsic characteristics of  a GM9 which have the potential to cause harm, ·either directly or 
indirectly.  Comparison of the  identified  hazards  of the  GMO(s)  with those  presented  by  the  non-
modified  organism  from  which  it  was  derived,  under  corresponding  conditions,  will  permit 
identification of  those hazards arising from the genetic modification.  It is important not to discount any 
hazard on the basis that it is unlikely to occur. 
2. The extent of  the consequences of  the hazard being realised 
For each  hazard  identified,  the  consequences  of the  hazard  occurring  should  be considered.  The 
evaluation of the extent of the consequences is affected by the environment into which the GMO(s)  is 
intended to be released and the manner of  the release. 
68 3.  The likelihood of  the hazard being realised 
·A major factor in  determining the likelihood of a hazard ·being realised  is  the characteristics of the 
environment into which the GMO(s) is iri.tended to be released.  · 
4.  ~timation  of  the risk posed by each identified hazard 
On the basis of  the hazardous characteristics, the likeliliood of them being realised and the magnitude of· 
the  consequences  a determination  of the  risk  of adverse  effects  should  be  made  for  each  hazard 
identified. 
5. Application of  management strategies for risks from the deliberate release of  GMO(s) 
'  .  .· 
If  for any release the estimated risk for any identified hazard is not at an acceptable level, the GMO(s) or 
the conditions of  the release should be modified to reduce the risk. 
6.  Determination of  the overall risk of  adverse effects 
An evaluation of the overall risk of adverse effects, whether direct or indirect, is determined from the 
combined effects of  the risk from each hazard taking into account any management strategies applied .. 
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ANNEX ill 
INFORMATION REQUIRED IN THE NOTIFICATION 
The notification for a deliberate release referred to in Part B or Part C of  the Directive is to include  . .  .  ' 
,as appropriate, the information set out below in the sub-Annexes. 
Not all the points included will apply to every case. It is to be expected that individual notifications 
will  address  only  the  particular  subset  of considerations  which  is  appropriate  to  individual 
situations. 
The level of detail- required  in response to  each subset of considerations  is  also  likely  to  vary 
according to the nature and the scale of  the proposed release. 
Annex III A  applies  to  releases  of all. types of genetically organisms other than higher plants. 
Annex III B applies to release of  genetically modified higher plants.  -
The term "higher plants" means plants which belong to the taxonomic groups Gymnospermae and 
Angiospermae. 
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INFORMATION REQUIRED IN NOTIFICATIONS CONCERNING RELEASES OF 
.  GENETICALLY MODIFIED ORGANISMS OTHER THAN IDGHER PLANTS 
I.  GENERAL INFORMATION 
A. Name and address of  the notifier (company or institute) 
B. Name, qualifications and experience of  the responsible scientist(s) 
C. Title of  the project 
II. INFORMATION RELATING TO THE GMO 
A. Characteristics of (a) the donor, (b) the recipient or (c) (where appropriate) parental 
- I 
organism(s): 
1.  scientific name; 
2.  taxonomy; 
3.  other names (usual name, strain name, etc.); 
4.  phenotypic and genetic markers; 
5.  degree of relatedness between donor and recipient or between parental organisms; 
6.  description of identification and detection techniques; 
7.  sensitivity, reliability (in quantitative terms) and specificity of detection and dentification 
techniques; 
8.  description of the geographic-distribution and of the natural habitat of the organism 
including information on natural predators, preys, parasites and competitors, symbionts 
and hosts; 
9.  potential for genetic transfer and exchange with other organisms; 
10. verification of the genetic stability of  the organisms and factors affecting it; 
11. pathological, ecological and physiological traits: 
(a)  classification  of  hazard  according  to  existing  Community  rules  concerning  the 
protection of human health and/or the environment; 
(b)  generation time in natural ecosystems, sexual and asexual reproductive cycle; 
(c)  information  on  survival,  including  seasonability  and  the  ability  to  form  survival 
structures e.g.: seeds, spores or sclerotia; 
(d)  pathogenicity:  infectivity,  toxigenicity,  virulence,  allergenicity,  carrier  (vector)  of 
pathogen,  possible  vectors,  B.ost  range  including  non-target  organism.  Possible 
activation of latent viruses (proviruses). Ability to colonize other organisms; 
(e)  antibioticresista.llce,  and  potential use ofthese antibiotics  in humans  and  domestic 
organisms for prophylaxis and  therapy; 
(t)  involvement  in  environniental  processes:  primary  production,  nutrient  turnover, 
" decomposition of  organic ma~er, respiration, etc. 
71 12.  Nature of  indigenous vectors: 
(a) sequence; 
(b) frequency of  mobilization; 
(c) specificity;  . 
(d) presence of  genes which, confer resistance. 
13.  History of previous genetic modifications. 
B. Characteristics of  the vector:. 
1.  nature and source of  the vector; 
2.  sequence oftransposons, vectors and other non-coding genetic segments used_ to construct 
the GMO and to make the introduced vector and insert function in the GMO; 
3.  frequency of  mobilization of  inserted vector and/or genetic transfer capabilities and 
methods of determination; 
4.  information on the degree to which the vector is limited to the DNA required to perform 
the intended function. 
C.  Characteristics of  the modified organism: 
1.  Information relating to the genetic modification: 
(a) methods used forthe modification; 
(b) methods used to construct and introduce the insert(s) into the recipient or to delete a 
sequence; 
(c) description of the insert and/or vector construction; 
(d) purity of  the ins.ert from any unknown sequence and information on the degree to 
which the inserted sequence is limited to the DNA required to perform the intended 
function; 
(e) sequence, functional  i~entity and location -of the altered/inserted/deleted nucleic acid 
segment(s) in question -..vith particular reference to any known harmful sequence. 
2.  Information on the final GMO: 
(a) description of genetic trait(s) or phenotypic characteristics and in particular any new 
traits and characteristics which may be expressed or no longer expressed; 
(b) structure and amount of any vector and/or donor nucleic acid remaining in the fmal 
construction of the modified organism; 
(c) stability of the organism in terms of  genetic traits; 
(d) rate and level of expression of  the new genetic material. Method and sensitivity of 
.measurement; 
(e) activity of the expressed protein(s); 
(f)  description of identification and detection techniques including techniques for the 
identification and detection of  the inserted sequence and vector; 
(g) sensitivity, reliability (in quantitative terms) and specificity of detection and 
identification techniques; 
(h) history of  previou~ releases or uses of  the GMO; 
(i)  health considerations: 
(i) toxic or allergenic effects of  the non-viable GMOs and/or their metabolic products; 
{ii)  product hazards;  ·  ..  · 
(iii) comparison of  the modified organism to the donor, recipient or (where 
72 appropriate) parental organism regarding pathogenicity; 
(iv) capacity for colonization; 
(v)  if  the organism is pathogenic to humans who are immunocompetent: 
,. diseases caused and p:1echanism of  pathogenicity including invasiveness and 
virulence, 
- communicability, 
- infective dose, 
- host-range, possibility'  of  alteration, 
- possibility of  survival outside of  human host, 
- presence of  vectors or means of dissemination, 
- biological stability, 
- antibiotic-resistance patterns, 
- allergenicity, 
- availability of  appropriate therapies. 
III.  INFORMATION RELATING TO THE CONDITIONS OF RELEASE AND THE 
RECEIVING ENVIRONMENT 
A. Information on the release: 
1.  description of  the proposed deliberate release, including the purpose(s) and foreseen 
products; 
2.  foreseen dates of  the release and time plannirig of  the experiment including frequency and 
duration of  releases; 
3.  preparation of  the site previous to the release; 
4.  sizeofthesite; 
5.  method(s) to be used for the release; 
6.  quantities of GMOs to be released; 
7.  disturbance on the sit~ (type and method of cultivation, mining, irrigation, or other 
activities); 
S  worker protection measures taken during the release; 
9.  post-release treatment of the site; 
10. techniques foreseen for elimination or inactivation of the GMOs at the end of the 
experiment; 
11. information on, and results of, previous releases of the GMOs, especially at different 
scales and in different ecosystems. 
B. Information on the environment (both on the site and in the wider environment): 
l.  geographical location and grid reference of the site(s) (in ca~e of notifications under 
Part C the site(s) of  release will be the foreseen areas of  use of  the product); 
2.  physical or biological proximity to humans and other signifiqmt biota; 
3.  proximity to significant biotopes or protected areas; 
4~  size of local population; 
5.  economic activities oflocal populations which are based on the natural resources of the 
area; 
6.  distance to closest areas protected for drinking water and/or environmental purpose; 
7.  cl~matic characteristics of the region(s) likely to be affected; 
S.  geographical, geological and pedological characteristics; 
9.  flora and fauna, inc1udingcrops, livestock and migratory species; 
73 10. description of  target and non-target ecosystems likely to be affected; 
11. a comparison of  the natural habitat of  the recipient organism with the proposed site(s) of 
release; 
12. any known planned developments or changes in land use in the region which could 
influence the environmental impact of  the release. 
IV.  INFORMATION RELATING TO THE INTERACTIONS BETWEEN THE GMOs AND 
THE ENVIRONMENT 
A. Characteristics affecting survival, multiplication and dissemination: 
I.  biological features which affect survival, multiplication and dispersal; 
2.  known or predicted environmental conditions which may affect survival, multiplication 
and dissemination (wind, water, soil, temperature, pH, etc.); 
3.  sensitivity to specific agents. 
B. Interactions with the environment: 
1.  predicted habitatofthe GMOs; 
2.  studies of  the behaviour and characteristics of  the GMOs and their ecological impact 
carried out in simulated  natural environments, such as microcosms, growth rooms, 
greenhouses;  · 
3.  genetic transfer capability: 
(a) post-release transfer of  genetic material from G\fOs into organisms in affected 
ecosystems; 
(b) post-release transfer of  genetic material from indigenous organisms to the GMOs; 
4.  likelihood of post-release selection leading to the expression of  unexpected and/or 
undesirable traits ii1 the modified organism; 
5.  measures employed to ensure and to verify genetic stability. Description of genetic traits 
\Vhich may prevent or minimize dispersal of genetic material. Methods to verify genetic 
stability: 
6.  routes of biological dispersal, known or potential modes of.interactioh with the 
disseminating agent, including inhalation, ingestion, surface contact, burrowing, etc.; 
7.  description of ecosystems to which the GMOs could be disseminated. 
C. Potential environmental impact: 
1.  potential for excessive population increase in the environment; 
2.  competitive advantage of  the GMO~  in relation to the unmodified recipient or parental 
organism(s); 
3.  identification and description of  the target organisms: 
4.  anticipated mechanism and result of  interaction betlveen the released GMOs and the target 
orgamsm; 
5.  identification arid description of  non-target organisms which may be' affected unwittingly; 
6:  likelihood of  post-release shifts in biological interactions or in host range; 
7.  known or predicted ef(ects on non-targetorganisms in the environment, impact on 
population levels of competitors: preys,· hosts, symbionts,predators, parasites and 
pathogens; 
8.  kno.wn or predicted involvement in biogeochemical processes; 
9.  other potentially significant interactions with the environment. 
.  74 V. INFORMATION ON MONITORING, CONTROL, WASTE TREATMENT AND 
EMERGENCY RESPONSE PLANS 
A. Mon~toring techniques: 
1. ·methods for tracing the GMOs, and for monitoring their effects; 
2.  specificity (to identify the GMOs, and to distinguish them from the donor" recipient or, 
where appropriate, the parental organisms), sensitivity and reliability of  the monitoring 
techniques; 
3.  techniques for detecting transfer of  the donated genetic material to other organisms; 
4.  duration and frequenGy of  the monitoring. 
B. Control of  the release: 
1.  methods and procedures to avoid and/or minimize the spread of  the GMOs beyond the site 
of  release or the designated area  for use; 
2.  methods and procedures to protect the site from intrusion by unauthorized individuals; 
3.  methods and procedures to prevent other organisms from entering the site. 
C. \V  aste treatment: 
1.  type of  waste generated; 
2.  expected amount of  waste; 
3.  possible risks; 
- 4.  description of  treatment envisaged. 
D. Emergency response plans: 
1.  methods and procedures for controlling the GMOs in case of unexpected spread; 
2.  methods for decontamination of the areas affected, e.g. eradication of the GMOs; 
3.  methods for disposal or sanitation of plants, animals, soils, etc. that were exposed during 
or after the spread; 
4.  methods for the isolation of  the area affected by the spread; 
5.  plans for protecting human health and the environment in case of  the occurrence of an 
'  . 
undesirable effect. · 
75 ANNEXIIIB 
INFORMATION REQUIRED IN NOTIFICATIONS CONCERNING RELEASES OF 
GENETICALLY MODIFIED IDGHER PLANTS (GMPHS) 
(GYMNOSPERMAE AND ANGIOSPERMA.E) 
A. GENERAL INFORMATION 
1.  Name and address of  the notifier (company or institute) 
2.  Name, qualifications and experience of  the responsible scientist(s) 
3.  Title of  the project 
B. INFORMATION RELATING TO (A) THE RECIPIENT OR (B) (WHERE APPROPRIATE) 
PARENTALPLANTS  . 
I.  Complete name: 
(a)  family name; 
(b)  genus; 
(c) 
(d) 
(e) 
spectes; 
subspecies; 
cultivar/breeding line; 
(f)  common name. 
2.  (a)  Information concerning reproduction: 
(i)  mode(s) of  reproduction; 
(ii) specific factors affecting reproduction, if any; 
(iii) generation time. 
(b)  Sexual compatibility with other cultivated or wild plant species. 
3.  Survivability: 
(a)  ability to form structures for survival or dormancy; 
(b)  specific factors affecting survivability, if any. 
4. Dissemination: 
(a)  ways and extent of dissemination; 
(b)  specific factors affecting dissemination, if any. 
5.  Geographical distribution of  the plant. 
6.  In the case of plant species not normally grown in the l\fember State(s), description of the 
natural habitat of the plant, including information on natural predators, parasites, competitors 
and symbionts. 
7.  Potentially significant interactions ofthe plant with organisms other thi:Ul plants in the 
ecosystem where .it is usually grown, ~eluding information on toxic effects on humans, 
animals and other organisms. 
C. INFORMATION RELATING TO THE GENETIC MODIFICATION 
1.  Description of the methods used for the genetic modification. 
2.  Nature and source of the vector used. 
3.  Size, source (name) of  do~or  organism(s) and intended fUnction of each constituent fragment 
of  the regionintended for insertion. 
76 D. INFORMATION RELATING TO  THE GENETICALLY MODIFIED PLANT 
I. Description of  the trait(s) and characteristiCs which have been introduced or modified. 
2:  Information on the sequences actuallyin.Serted/deleted: 
(a) size and structure of  the insert and m~thods  used for its characterisation, including 
. information on any parts of  the vector introduced in the GMPH or any carrier or foreign 
. DNA remaining in the GMPH;. ·  . 
(b) in case of  deletion, size and function of  the deleted region(s); 
(c) location of  the insert in the plant cells (integrated in the chromesome, chloroplasts, 
mitochondria, or maintained in a non-intregated form), and methods for its determination; 
(d)  copy number of  the insert. 
3.  Information on the expression of  the insert: 
(a)  information on the expression of  the insert and methods used for its characterization; 
(b)  parts of  the plant where the insert is expressed (e.g. roots, stem, pollen, etc.). 
4  ..  Informationen on how the genetically modified plant differs from the recipient plant in: 
(a)  mode(s) and/or rate of  replication; 
(b)  dissemination; 
(c)  survivability. 
5.  Genetic stability of  the insert. 
6.  Potential for transfer of  genetic material from the genetically modified plants to other 
organisms. 
7.  Information on any toxic or harmful effects on human health and the environment, arising 
from the genetic modification. 
8.  Mechanism of interaction between the genetically modified plant and target organisms (if 
applicable). 
9.  Potentially significant interactions with non-target organisms. 
10. Description of detection and identification techniques for the genetically modified plant. 
11. Information about previous releases of  the genetically modified plant, if applicable. 
E.  ThTfORMATION RELATING TO THE SITE OF RELEASE (01\'L  Y FOR NOTIFICATIONS 
SUBlvfiTTED PURSUANT TO ARTICLES 6, 6a,  6b and 6c) 
1.  Location and size of the release site(s). 
2.  Description of  the release site ecosystem, including climate, flora and fauna. 
3.  Presence of  sexually compatible wild relatives or culivated plant species. 
4.  Proximity to officially recognized biotopes or protected areas which may be affected. 
F.  INFOR1v1ATION RELATING TO THE RELEASE (ONLY FOR NOTIFICATIONS 
SUBWTTED PURSUANT TO ARTICLES 6,  6a,  6b and 6c) 
l. Purpose of  the release. 
2.  Foreseen date(s) and duration of  the release. 
3.  Method by which the genetically modified plants will be released. 
4.  Method for preparing and managing the release site, prior to, during and post-release, 
including cultivation practices and harvesting methods. 
5.  Approximate number of plants (or plants per m
2
). 
77 G.  INFORMATION  ON  CONTROL,  MONITORING,  POST-RELEASE  AND  WASTE 
TREATMENT PLANS  (ONLY FOR NOTIFICATIONS  SUBMITTED  PURSUANT  TO 
ARTICLES 6, 6a, 6b and 6c) 
1.  Any precautions taken:  . 
(a).·  distance(s) from sexually compatible plant species; 
(b)  any measures to minimize/prevent pollen or seed dispersal. 
2.  Description of  methods for post-release treatment of  the site. 
3.  Description of  post-release treatment methods for the genetically modified plant material 
including wastes. 
4.  Description of  monitoring plans and techniques. 
5.  Description of  any emergency plans. 
H.  INFORMATION ON THE POTENTIAL ENVIRONMENTAL IMP  ACT FROM THE 
RELEASE OF THE GENETICALLY MODIFIED PLANTS 
1.  Likelihood of  the GMPH becoming more persistent than the recipient or parental plants in 
agricultural habitats or more irivasive in natural habitats. 
2.  Any selective advantage or disadvantage conferred to other sexually compatible plants 
spec1es, 
which may result from genetic transfer from the genetically modified plant. 
3.  Potential environmental impact of  the interaction between the genetically modified plant and 
target organisms (if applicable). 
4.  Possible environmental impact resulting from potential interactions with non-target 
orgamsms. 
78 ANNEX IV 
ADDITIONAL INFORMATION REQUIRED IN THE CASE OF NOTIFICATION FOR PLACING 
ON THE MARKET  .  . 
A.  '.(he following information shall be provided in the notification for placing on the market of 
products, in addition to that of  Annex ill: 
1.  name of  the product and names of  GMOs contained therein; 
2. ·  name of  the manufacturer or distributor and his address iii the Community; 
3.  specificity of  the product, exact conditions of  use including, when appropriate, the type 
of  environment and/or the geographical area(s) of  the Community for which the product 
is suited; 
4.  t)rpe of expected use: industry, agriculture and skilled trades, consumer use by public at 
large. 
5.  information relating to the introduced genetic modification which could be of  relevance 
to  the establish!rient of a  possible register of modifications  introduced in organisms 
(species). This may include nucleotide sequences or other type of information wh!ch is 
. relevant to the inclusion in such a register.  · 
B.  The following information shall be provided, when relevant,  in addition to that of point A,  in 
accordance with Article 11 of  this Directive:  .. 
1.  measures to take in case of  unintended release or misuse; 
2.  specific instructions or recommendations for storage and handling; 
3.  estimated production in and/or imports to the Community; 
4.  proposed packaging.  This must be appropriate so as to avoid unintended release of the 
GMOs during storage, or at a later stage;  · 
5.  proposed  labelling·.  This  must include,  at least in  summarized form,  the information 
referred to in points A  1, A. 2, A.3, B.  1 and B. 2 
C.  The  following  information  concerning  labelling  shall  be  provided  m  the  notification,  m 
accordance with Article 11 of  this Directive: 
1.  A Proposal for a mandatory labelling "this product contains GMOs", either on a label or 
in accompanying document, whenever there is evidence of  the presence of GMOs in the 
product. 
2.  A  Proposal  for  a  mandatory  labelling "this  product may contain  GMOs" where the 
presence of GMOs  in  a·  product cannot be excluded  but there is  no  evidence of any 
presence of  GMOs. 
79 ·ANNEXV 
CRITERIA FOR CLASSIFICATION OF RELEASES PROVIDED FOR IN ARTICLE 6 
A.  Part B releases shall be classified into category I if  they satisfy the criteria set out below 
1.  The taxonomic status and the ·biology (e.g. mode of  reproduction and pollination, ability to. 
cross  with  related  species)  of the non-modified  (recipient)  organism  shquld  be  well-
known; 
2.  There  should  be  sufficient  la;lowledge  about  the  safety  for  human ·health  and  the 
environment of  the non-modified (recipient) organism in the environment of the release; 
3.  The genetically  modified -organism  should  not present  additional  or· increased risks  to 
human health and/or the environment under the conditions of  the experimental release that 
are  not presented by releases  of the  cOrresponding  non-modified  organism in terms  of 
pathogenicity, allergenicity, toxigenicity.  The -capacity to spread in the environment and 
invade  other· unrelated  ecosystems  and  capacity  to  transfer  genetic  material  to . other 
organisms in the environment should not create any adverse effect. 
B.  Part B releases shall also be classified in:to Category I if the release is similar, in terms of the 
genetically  modified  organism(s)  involved  and  the  conditions  applied,  to  other  releases 
.  which have already been given co.qsent to and where the results submitted in accordance with 
Article 8 have not shown risks to human health and/or the environment. 
80 ANNEX VI 
GUIDELINES FOR THE ASSESSMENT REPORTS 
FORESEEN BY ARTICLE 12 
The assessment report foreseen by Article 12 should include in particular the following : 
i' ......  ~· 
1.  Identification  of the  characteristics  of the recipient  organism  which  are  revelant  to  the 
assessment of the GMO(s)  in question.  Identification of any  known risks  to  f!uman  health 
and/or the environment resulting from the release into the environment ofthe recipient non-
modified organism; 
2. ·  Assessment of whether the genetic modification has  been characterised  sufficiently ·for the 
purpose of evaluating any risks to human health and/or the environment; 
3.  Detailed description of  the result of  the genetic modification in the modified organism; 
4.  Identification of. any new risks to human health and/or the env'ironqtent that may arise from the 
release of the  GMO(s)  in question  as  compared  to  the  release  of the. corresponding  non-
modified organism(s) based on the risk assessment as described in Annex II; 
5.  A conclusion on  whether the ·GMO(s) in question should be placed on the market in or as (a) 
product(s)  and  under which conditions  or whether  an  additional  assessment  is  required  on 
certain aspects. The aspects which require additional assessment should be specified. 
81 ANNEXVIT 
The monitor~g plan foreseen by Article 11(2) shall provide for the appropriate methods and 
measures to  identify .  any relevant direct,  indirect,  immediate  or delayed  effects  on human 
health and/or the  enviionm~nt taking into  account in particular the following  elements, if 
appropriate: 
• . human health considerations 
- potential of  the GMOs for pathogenic, toxic or allergenic effects 
capacity of the GMOs for colonization 
- potential  of the  G:MOs  to  compromise  the  efficacy  of therapeutic,  prophylactic  or 
diagnostic measures. 
•  environmental considerations 
- p6tential of  the GMOs to persist and spread in the environment 
- pote~tial of  the GMOs for interactions with target or non-target organisms 
- potential of  the GMOs to affect population dynamics 
•  effects resulting from potential horizontal gene transfer 
•  phenotypic and genetic stability of the GMOs 
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